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February ValueR:x's 40,000 square foot state-of-the-art mail service facility in Davenport, Iowa became fully operational. 
Shareholders Rights Plan adopted by Board of Directors to give the company adequate time to consider and evaluate any unsolicited takeover offers. 
April Value Behavioral Health awarded a subcontract from Group Health Incorporated (GHI) to provide mental health and chemical dependency benefits to more than 600,000 City of New York employees and their dependents. 
Acquisition of Burke-Taylor Associates, an employee assistance program company in Raleigh/Durham, NC, to further strengthen and enlarge our network of providers. 
Value Health, Inc. is a leading 
provider of specialty managed 
care benefit programs and 
health care information ser­
vices. Value Health companies 
hold leading market shares in 
all six of our product lines. 
Our specialty managed care 
benefit programs are designed 
to enhance the quality and 
control costs in selected health 
care sectors that are of partic­
ular concern due to their size, 
rapid cost escalation and 
potential for overutilization. 
These areas include prescrip­
tion drugs, mental health and 
substance abuse, and work­
ers' compensation. 
Our health care information 
services are based upon the 
use of clinical and data analy­
sis to guide health care deci­
sion making. These products 
include clinically based precer­
tification and claims review, 
provider profiling, claims cost 
analyses, evaluation and man­
agement of health benefit 
providers, disease manage­
ment, and health policy and 
management consulting. 
Value Health provides ser­
vices to more than 64 million 
people, and our customers 




with $40 million 
in revenues 
Company founded; 
received equiry funding 






(now ValueRx), and 
Health Information 
Designs acquired 
May Value Health entered a strategic partnership with Pfizer Inc to build major new disease management capabilities. 
Value Health Sciences created breakthrough cancer treatment guidelines; first of a series to focus on the use of bone marrow transplantation in breast cancer treatment. 
Reported record first quarter revenues of$197 million, a 44% increase from first quarter 1993; net earnings of $.28 per share.t 
June Acquisition of Community Care Network, Inc. (CCN), the nation's largest specialty workers' compensation managed care provider with more than 13 million covered lives. 
1988 
Year closed 
with $59 million 
in revenues 
Value Health Sciences 
founded, building upon 
clinical research devel­




with $82 million 
in revenues 
Medical Review System 
(MRS) introduced by 
Value Health Sciences 











by parent cc 
July October Reported record second quarter revenues of $218 million, a 48 % increase from second quarter 1993; nee earnings of $.31 per share.t Preferred Works certified as an approved managed care plan for workers' compensation by the Scace of Minnesota's Department of Labor and Industry, becoming the first third-party administrator ro be approved by the state. August 
November 
Insurance Services Group, incorporating the CCN and Preferred Works workers' compensation and group heal ch businesses, created; David Noone, former President and CEO of Preferred Works, named as President and CEO. James E. Buncher, CCN Chairman, President and CEO, is appointed ro che Senior Management Committee of Value Health. 
Reported record third quarter revenues of $252 million, a 42% increase from third quarter 1993; net earnings of $.35 per share.* 
Value Health announced termination of discussions regarding possible sale ofValueRx. Acquisitions of RxNec, Inc. of California, Prescription Drug Service, Inc., and its affiliate Prescription Drug Service West, Inc., pharmacy benefit management companies. Increases covered lives for ValueRx ro more than 8 million. 
December ValueRx and CCN team up ro provide a trend-setting program for the State of Arizona with a workers' compensation pharmaceutical benefit program covering approximately 8 0,000 state workers. 
Year closed 
with S 124 million 
in revenues, 





by parent company 
199 1 
Year closed 
with S 196 million 
in revenues, 
$13 million 
in pretax profits 
Cost Containment 
Corporation acquired; 
combined with ValueRx 
Value Health initial 
public offering raises 
$38 million, opens 
trading on NASDAQ 
1992 
Announced sale of National Foot Care Program back to its founder, Dr. Claude Oster. 
Year closed 
with $366 million 
in revenues, 
$27 million 
in pretax profits 
Practice Review System 
(PRS) introduced by 
Value Health Sciences 
Lewin ICF (now Lewin­
VHI) acquired 
Stokeld Health Services 
Corporation acquired; 
integrated with ValueRx 
Value Health begins 
trading on the NYSE 
Recognized by Fortune as 
93rd among America's 
fastest growing companies 
Two secondary offerings 
raise $161 million; 




with $689 million• 
in revenues, 
$56 million* in 
pretax profits 




form Value Behavioral 
Health (VBH) 
Raleigh Group, the 
Center for Human 
Resources, and 
Associated Prescription 
Services acquired and 
integrated with existing 
Value Heal th businesses 
Recognized by Fortune 
as 80th among 
America's fastest 
growing companies 
Value Health and E.M. 
Warburg, Pincus & 
Co., Inc. provide fund­




with $976 million* 
in revenues, 
$89 million* 
in pretax profits 
ValueRx Mail Service 
Iowa faciliry becomes 
operational 
Board adopts 




Value Health and Pfizer 
create joint venture part­
nership ro develop spe­




Value Health crosses 
$1 billion mark in 
annualized revenues 
in third quarter 
Communiry Care 
Network acquired; 
integrated with Preferred 
Works to form Insurance 
Services Group 
RxNet of CA, Prescrip­
tion Drug Service, Pre­
scription Drug Service 
West acquired; integrated 
with ValueRx 
*before merger-related charges 
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Revenues Pretax Earnings• Earnings Per Share• Stockholders' Equity Covered Lives 
(Dollars in thousands, except per shore dato) 1994 1993 1992 
Revenues: 
Prescription Drugs $654,405 $439,842 $ 225,461 
Mental Health 198,599 161,643 114,223 
Insurance Services 67,268 35,895 1,409 
Information Services 40,721 36,878 12,711 
Other 9,710 7,413 6,128 
Investment Income 5,700 7,784 5,711 
Total Revenues $976,403 $689,455 $ 365,643 
Earnings from Continuing Operations before 
Merger-Related Expense and Taxes $ 88,559 $ 56,085 $ 27,373 
Pretax Margin 9.1% 8.1% 7.5% 
Earnings from Continuing Operations Per Share 
Excluding Merger-Related Expense $ 1.29 $ 0.82 $ 0.53 
Stockholders' Equity Per Share $ 9.68 $ 8.07 $ 7.58 
Market Price of Common Stock: 
Range $ 30.13 - $52.00 $ 22.00 - $41.00 $ 18.33 - $40.25 
Close $ 37.25 $ 31.50 $ 39.63 
*From continuing operations, excluding merger-related expense 
� 
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The Value Health 
1994 Annual Report 
is dedicated in memory of 
Michael H. Walsh July 8, 1942-May 6, 1994 
Chairman and Chief Executive Officer 
Tenneco 
Value Health Board Member 














To the Employees, Directors and 
Owners of Value Health: 
I started writing this letter while on an airplane, feeling that if 
there was ever a year that needed to be viewed from 30,000 feet, 
it was 1994. 
It was a year of such great change that it takes some distance 
from its peaks and valleys to properly judge the forward progress 
that was made. Remember back, if you can, to what the world 
was like in health care when the year began. The external con­
text was somewhat foreboding. There was the real prospect of 
disruptive national health reform coming from Washington. 
Managed care was caught up in the legislative cross fire, and 
investor concerns about that were reflected in sluggish stock 
market performance. In our own world, we were facing a new 
kind of competitive challenge in the prescription drug manage­
ment market as a result of Merck's acquisition of Medco, with 
many analysts predicting that pricing and margins would col­
lapse as a result. 
But stepping back from what seemed over the year to be 
constant crosscurrents, we can see now that the tide was swing­
ing strongly in favor of private market approaches to health care 
reform, to managed care, and to companies like Value Health. 
It will prove, I think, to have been a watershed year nationally, 
and a year of confirmation of Value Health's basic strategies. 
Health Care Reform 
I will not dwell at any length on the national health care reform 
scene, though our Lewin-VHI subsidiary consistently made 
the front pages as the most credible source of cost estimates on 
the various reform plans. The whole national debate proved 
that the country prefers careful, incremental, market-based 
change, not untested and revolutionary governmental schemes. 
And, as if to punctuate the collapse of the Grand Designs, the 
data has now emerged to show that in 1994 employer health care 
costs actually went down for the first time in recorded history. 
While it is not without problems, managed care is working. 
Sorting through the year's events to identify the key out­
comes for Value Health, I would suggest that we focus on just 
Bringing Science to 
the Art of Managed 
Care ... 
Disease by Disease 
" .. stepping back from what 
seemed over the year to be constant 
crosscurrents, we can see now that 
the tide was swinging strongly in 
favor of private market approaches 
to health care reform, to managed 
care, and to companies like Value 
Health. It will prove, I think, to 
have been a watershed year nation­
ally, and a year of confirmation of 






three key messages. They are: ( 1) our very positive financial and 
ocher results; (2) our emerging competitive advantage as an inde­
pendent prescription benefit manager (PBM); and (3) the new 
field of disease management as a confirmation of our past strate­
gies and as a direction for the future. 
1994 Results and Achievements 
Lee's scare with the year's results. le was, by any measure, an 
excellent year for Value Health. Quarter after quarter, our 
financial progress met or exceeded expectations, with che year 
ending with a 42% increase in revenues and a 59% increase in 
earnings per share before merger-related expense. We closed 
out 1994 having broken through the $1  billion mark in annual­
ized revenues and with operating margins up a full point, co 
9 . 1  %. We registered strong internal sales growth with annual­
ized revenues from new accounts scarring in 1994 up 82% 
over the prior year. 
Going beyond purely financial results, we racked up a 
number of ocher achievements: 
we successfully integrated American PsychManagemenc and 
Preferred Health Care, the latter acquired in December of 
1993, co form the nation's largest managed mental health 
company, Value Behavioral Health (VBH). Substantial cost­
saving synergies were achieved, as well as improvements in 
service performance as we preserved che best practices of both 
predecessor companies; 
at ValueRx, we completed and brought on-line one of the 
industry's most advanced mail service prescription facilities, 
capable of processing 25,000 scripts per day, and extended 
our formulary programs with drug manufacturers co 
97% of our covered lives; 
1987 1988 
$40 million in revenues $59 million in revenues 
"It was, by any measure, an excellent year 
for Value Health. Quarter after quarter, 
our financial progress met or exceeded 
expectations, with the year ending with 
a 42% increase in revenues and a 59% 
increase in earnings per share before 
merger-related expense .... All in all, it 
was a great year and we'd be delighted 
with 10 more just like it." 
we entered into a precedent-setting disease management 
contract with Pfizer Inc, creating an important new profit 
center for our Value Healch Sciences subsidiary; and 
we expanded our position in che workers' compensation 
managed care business by acquiring che leading preferred 
provider organization company in chat business, Community 
Care Network (CCN) of San Diego. 
I stress chose steady and positive results because, in the 
course of a year of stock marker ups and downs, investors might 
well have lose sight of our very strong fundamentals. These 
resulcs were che produce of che effort of all of our 4400 employees 
nationwide, and I wane co take chis opportunity co thank each 
one for his or her continuing effort. This was a team result. 
Special thanks and best wishes go co Steve Linehan, Claude 
Oster and Matt Thomas, who left our senior management group 
at the end of the year co pursue ocher opportunities outside 
Value Health. 
Were there disappointments? Of course. Sales were slow at 
VBH as staff were distracted with integration casks. Our new 
rate under the Ford contract at ValueRx proved to involve a loss, 
1989 1990 
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but the good news on that front was that we were able to absorb 
the unplanned loss through over-plan results elsewhere and still 
meet investor expectations. Moreover, in January 1995 we won 
a rebid for Ford at a significant rate increase which will restore 
that important contract to profitability. All in all, it was a great 
year and we'd be delighted with 10 more just like it. 
The Future of Pharmacy Benefits Management 
That gets us to the second subject - the future of the PBM busi­
ness in general and of our PBM subsidiary, ValueRx, in particu­
lar. The PBM world was convulsed during the summer of 1993 
with the announcement that Merck, the world's largest pharma­
ceutical manufacturer, would vertically integrate into drug distri­
bution by buying one of the largest PBMs, Medco Containment 
ervices. Frankly, neither we nor most other PBMs or manufac­
turers had seen that bold move coming. Uncertainty about the 
future shape of the industry prevailed, exacerbated by drastically 
lower PBM pricing offered by Medco to the Big Three auto 
companies during their bidding process in the fall of 1993. 
ValueRx was able to retain and even expand its business with 
Ford in that process, but as I noted earlier at a lowered rate that 
later proved to produce an earnings loss. 
We responded to the Merck move by seeking to develop 
contract-based alliances with other drug companies, and that 
strategy unfolded positively as we entered into an exciting new 
arrangement with Pfizer in May. But then the situation seemed 
to de�eriorate when two other drug manufacturers, SmithK!ine 
Beecham and Lilly, announced purchases of two more of our 
PBM competitors. Clearly, given the large amounts being paid, 
we had an obligation to our shareholders to investigate options 
with regard to ValueRx. We did just that, with vigor, in the sec­
ond and third quarters of last year. 
199 1  1992 
$196 million in revenues $366 million in revenues 
"We responded ... by seeking to develop 
contract-based alliances with other drug 
companies, and that strategy unfolded 
positively as we entered into an exciting 
new arrangement with Pfizer in May." 
As I look back on that activity now and reflect on the many 
conversations we had with drug company executives, it seems 
clear we were all playing out yet another version of the drama 
that was taking place on the national stage - the conflict between 
revolution and incrementalism, or that between bandwagon psy­
chology and sober assessment. Three drug companies had opted 
for the revolutionary step of vertical integration - of buying the 
very managed care instrumentalities that were driving down their 
margins. But as it turned out, most of the drug industry ended 
up by disagreeing with that strategy, feeling that it was preferable 
not to compete with their customer PBMs and instead to main­
tain open channels of distribution. Moreover, as time went on, 
the vertical integration strategy came under closer scrutiny from 
federal antitrust regulators, further discouraging drug manufac­
turers from buying PBMs. These manufacturers did indeed 
want to talk to us, but as it turned out not about buying our 
PBM (or anyone else's). Their interest was instead in diversify­
ing into the new field of disease management (more on that 
later). By the third quarter, it was clear that the urge to acquire 
PBMs was not shared by the remaining drug manufacturers. 
In the meantime, we began to see a stabilization of pricing 
in the PBM business as the new drug company owners conclud­
ed that they could not or would not operate their distribution 
subsidiaries at a loss in an effort to shift market share. So we 
determined for all of these reasons that we would not sell 
ValueRx, feeling that this valuable and profitable business was 
one we wanted to keep. 
1993 1994 
$689 million in revenues $976 million in revenues 
c • 
" ... we began to see a stabilization of 
pricing in the PBM business as the new 
drug company owners concluded that 
they could not or would not operate 
their distribution subsidiaries at a loss 
in an effort to shift market share. So 
we determined for all of these reasons 
that we would not sell ValueRx, feeling 
that this valuable and profitable busi­
ness was one we wanted to keep." 
$1 Trillion in U.S. Health Care Spending 
Value Health's products cover 20% 
to 30% of the health care dollar 
Other health spending 
Workers' compensation & 
other VH service areas 
Mental health 
Prescription drugs 
When we announced that decision in November, some Disea 
speculative investors concluded that our PBM prospects were means foe 
somehow diminished and they sold our stock, driving the price order to ir 
down for a time. Our view, however, is precisely the opposite. compame: 
We now find ourselves as one of the largest independent PBMs, capital in• 
able to market our clinical independence as an important services. I 
distinction given manufacturer ownership of our three largest 
competitors. Moreover, these competitors will no doubt lose 
some of their entrepreneurial character as they are integrated, 
and they will be hampered in making acquisitions of other 
PBMs given Federal Trade Commission concerns. So far, our 
judgment seems confirmed as our business continues to grow 
and our 1995 margins are holding up at the 1993 levels that 
prevailed before the PBM acquisition activity began. 
have alrea, 








Disease Management Initiatives eating thi: 
This gets me now to the third subject, that of disease manage- Board me 
ment, where in fact we are hoping to collaborate closely with the premature 
pharmaceutical industry. We believe that this new field is so and comr 
important to managed care and to Value Health that we have 
devoted the entire essay portion of this annual report to it. So 
let me only introduce the subject here. 
Value Health and drug manufacturers face something of the 
same strategic challenge - how do we carefully diversify beyond 
our current borders? At Value Health, we have products that 
address 20% to 30% of the $ 1  trillion in U.S. health care spend­
ing; drug companies, which are the largest health care organiza­
tions in the world, address only 7% to 10% of spending. Yet we 
both have need� and ambitions to leverage our current capabili­
ties into more of the health care spending pie. 






er, some "I Disease management is how we can do chat. Simply put, it 
Jeers were means focusing managed care techniques on high-cost diseases in 
rig the price . order co improve patient outcomes and lower costs. For drug 
e opposite. companies, it is a way co leverage their disease knowledge and 
dent PBMs, capital in a focused way beyond "hard goods" into health care 
Jrtant services. For Value Health, it is the natural extension of what we 
ree largest have already done in mental health - customizing managed care 
loubc lose cools co focus on a particular disease state - and it fully uses the 
negrated, clinical and strategic skills of our Value Health Sciences and 
f ocher Lewin-VHI teams. For consumers of health care, it represents 
So far, our what we would all like co have - the ability co choose a healch 
:s to grow 
I 
plan based on its performance in preventing �nd curing disease. 
vels that If chis intrigues you, please read on in chis report. Disease 
management will be an important part of Value Healch's future. 
Let me close on a personal note by saying that we are dedi­
cating chis report co the memory of Mike Walsh, our former 
� manage-
I 
Board member and my friend for almost 30 years. Mike's 
sely with the premature death deprived America of one of its great business 
1eld is so 
t we have 
c co it. So 





ling. Yet we 
nc capabili-
and community leaders, but he left behind a wonderful family 
and a large number of organizations and people who are better 
for having known him - including all of us at Value Health. 
We thank you for your continued support. 
- �-
Robert E. Patricelli 
Chairman of the Board and Chief Executive Officer 
"Value Health and drug manufacturers 
face something of the same strategic 
challenge - how do we carefully diversify 
beyond our current borders? At Value 
Health, we have products that address 
20% to 30% of the $ 1  trillion in U.S. 
health care spending; drug companies, 
which are the largest health care organiza­
tions in the world, address only 7% to 
I 0% of spending. Yet we both have 
needs and ambitions to leverage our 
current capabilities into more of the 
health care spending pie. " 
Specialty Benefit Programs 
Employers are finding chat certain areas of 
their health care benefits, in particular pre­
scription drugs, mental health and substance 
abuse, and workers' compensation programs, 
are growing at rates in excess of general med­
ical care inflation. 
"Generalist" managed care techniques as 
employed in the medical-surgical world are 
not as effective in improving quality and 
reducing costs in these areas as are specialized 
techniques tailored to each segment. 
Large self-insured employers, managed care 
organizations, and insurers are increasingly 
carving out the management of one or more 
of these rapidly escalating segments from 
the rest of their benefits programs, and giv­
ing them to specialty managed care compa­
nies like Value Health to administer. (For 
example, there are almost as many people 
in carve-out managed mental health pro­
grams - over 42 million - as there are enroll­
ed in HMOs nationwide.) In customizing 
select provider networks, utilization review, 
case managementi'techniques and clinical 
protocols, Value Health enhances quality 
and reduces costs of care in the areas of 
pharmacy, mental health, and workers' 
compensation programs. 
Health Care Information Services 
Over 1 4% of the U.S .  economy is devoted to 
health care services and products . But, com­
pared to other sectors of the economy, there 
is an acknowledged lack of meaningful infor­
mation available to those responsible for 
making informed decisions about how health 
care resources are spent. 
Value Health's health care information 
services are based upon the use of sophisti­
cated clinical tools, data analyses, and expert 
consulting to guide health care decision 
makers in the public and private secto rs . 
Programs are offered through an unrivaled 
450-person team of clinicians, analysts , and 
managers in Value Health Sciences, Lewin­
VHI, and Value Health Management .  
A variety of cons ulting services, data analy­
ses, clinical software programs, and disease 
management services are available to our 
clients , including: 
strategic and organizational cons ulting 
to assist providers in key decisions ; 
clinical protocols to identify inappropri­
ate care before and after it's given; 
profiling techniques to improve manage­
ment of provider networks, util ization, 
and patient outcomes; 
utilization analyses to detail how money 
is spent and recommend improvements; 
and, 
assistance to payers in improving 
the performance of their managed 
care vendors. 
Specialty Benefit Programs 
• 
ValueRx: 
Pharmacy Benefits Management 
Qi Employe rs s pend approximate ly 7 %  to 8 %  of the ir be ne fit dollars on presc rip- E tion drugs, and chose c os ts are ris ing 15% annually, acc ording to rece nt � . d � m usrry s urve ys . v 
1/1 ... This c os t esc alation res ults fr om incre ase d and s ome times inappropriate drug � utiliz ation, ne w produc t de ve lopme nts, " trading up" on drug s elec tions, O d . . 0 an pnce mc re ases .  ValueRx's � 
I � "' i 
Value Rx is the nation's leading inde pe nde nt pharmac y be ne fit manage r, provid- programs J; � ] � ing manage d presc ription drug programs to e mploye rs and inte rme diaries who § . 9 i:: 8 h. b fi f h . d' c al I b d now cover · - ::::: o ""6 c arve our t 1s e ne H rom t e1 r  me 1 p ans to ette r manage c os es an . . 3 ' §  � > 
e nhance quality. 1 6 mi l lion 8 ,.... 8 
r rn ,....; \Q Value Rx se rvices its c lie nts through a nationwide ne twork of ove r 37, 000 re tail ives. 00 ,.... ,.... pharmac ies whic h are linke d through our on- line c ompute r s ys te m. Programs 1 /93 1 /94 1 /95 typic ally s ave c us tome rs 25% to 45% c ompare d to unmanage d drug c laim c os ts . 
Value Behavioral Health: 
Mental Health, Substance Abuse, and Employee Assistance Programs 
Qi " > 1/1 
· - Qi 1/1 .. Employe rs s pe nd 8 %  to 10% of their be ne fit dollars on me ntal he alth and s ub- � � s tance abuse programs.  In addi rion to the inc re ases in direc t be ne fi r c os es, indi- i e­'-rec t e xpe nses - s uch as chose ass oc iate d with abse nteeis m, dec re as ed producrivi- � 8 
I 
ty, and highe r workers ' c ompe ns ation c laims - acc ount for te ns of billions of o ,5 V J:  dollars more . '- co 
s >  
t 
Value Be havioral Health (VBH) is the nation's larges t  provide r of manage d O E' me ntal he alth, s ubs tance abuse , and e mployee ass is tance programs. VBH pro- VBH's t E! vides programs to large se lf -i ns ured e mploye rs who c arve out thes e  be ne fits programs "' &. e fr om the ir medic al plans as well as by s ubcontrac t to HMOs and ins urance � � � < Q. . VBH h h . h II d b · d· H al h M now cover · - > > c ompames .  , t roug i ts w o y owne s u  s1 1 ary e t anage me nt -;:; :.::: :.::: Strate gies Inte rnacional, provides me ntal he alth utiliz ation re vie w se rvices to over � . §  . §  nearly 5 million military de pe nde nts through CHAMPUS (The Civilian 2 1  mil l ion 
6 I :"::: 
:"::: 
He alth and Me dic al Program of the U niforme d Se rvices ). • rn ! � l ives. rn ..... N VBH's c ompre he ns ive be havioral he alth programs utilize a ne twork of ove r 1 193 1 ;95 36, 000 prac titione rs and inpatie nt fac ilities nationwide . VBH se rvic es offe r 1 /94 
c us tome rs s avings of 20% co 40% as c ompare d to unmanaged programs .  
Value Health Insurance Services Group: 
Managed Workers ' Compensation, Group Health and Related Services 
Workers ' c ompe ns ation c os ts to e mploye rs are now in e xcess of $7 0 billion a ye ar. More than 40% of chat ris ing c os t is c ompose d of me dic al e xpe nses .  
Value He alth's Ins uranc e Se rvices Group (ISG) inc ludes our manage d worke rs ' c ompe ns ation and group he alth se rvices .  Our inte grate d res ources offe r ne twork- base d c os t manage me nt and tre atme nt s trate gies for me dic al and inde mnity c ove rages and work- re late d injuries .  Programs inc lude 
c ompre he ns ive uriliz arion manage me nt, c laims adminis tration, dis ability manage me nt, and health c are data analys is . We have the larges t  s pe cialty ne twork of ne arly 8 5, 000 provide rs offe ring workers ' c ompe ns ation me dic al, behavioral, and presc ription drug se rvices to more than 14 mil ion be ne fic iaries .  Through our Pre fe rre d Works and Community Care Ne twork c ompanies, ISG de mons trates s avings of 10% ro 50% c ompare d co unmanage d programs. 
ISG programs 
now cover over 
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Mail Service: A sta nd-a lone or fully i ntegra ted complement c o  the retai l pha r­ma cy progra m, a llowi ng members c o  recei ve mai ntena nce prescri pti on drugs conveni enc ly by mai l. Va lueRx's pri mary mai l servi ce faci li ty i n  Iowa ,  a sta te- of the-a rc ,  fully a utoma ted complex i ncludi ng a n  i ntelli gent di spensi ng system, a dva nced ma teria l ha ndli ng techni ques, a nd i ntegra ted drug uti li za ti on revi ew, i s  ca pa ble of di spensi ng 25, 000 prescri pti ons per da y; 
National Formulary: Independent gui da nce for doctors a nd pa ti ents on qua liry, cost- effecti ve prescri pti on drug choi ces c ha t  ca n ea rn ma nufacturer reba tes; developed by Va lueRx wi th i nput from the Na ti ona l Pha rma cy a nd Thera peuti cs Commi ttee, selected subspecia li sc s, a nd cli ni ca l pha rma ci sts; 
Clinical Services: Compr ehensi ve progra ms i ncludi ng computeri zed drug uti li za ti on revi ew (DU Rba se™ ) to i dentify i ndi vi dua ls potentia lly a t  hi gh ri sk for drug-i nduced i llnesses; physi cia n  profili ng c o  i dentify physi cia ns wi th i na p­propria te prescri bi ng pa tterns who then recei ve focused educa ti ona l progra ms; pa ti ent profili ng a nd educa ti on progra ms; a nd di sea se ma na gement. 
Client-Centered Account Management: Tea ms ofVBH personnel provi d­i ng customer- speci fic servi ces, i ncludi ng 24- hour, c oll-free servi ce, sta ffed by ma sters- level cli ni cia ns, c o  help members a ccess pra cti ti oners sui ted to thei r pa rti cula r needs a nd loca ti ons; 
Case Management: Specia li zed menta l hea lth trea tment pla ns developed by tea ms of pa ti ents' thera pi sts, VBH regi stered psychia tri c  nurses, socia l work ers, a nd physi cia ns; 
Clinical Groups (CGs} : Specia lly selected loca l groups of thera pi sts a nd faci li­ti es provi di ng comprehensi ve servi ces a nd a greei ng to cli ni ca l a nd outcomes sta nda rds i n  return for prefe rred sta tus a s  provi ders; 
Employee Assistance Programs: Work- si te- ba sed employee a ssi sta nce a cti vi ti es a nd specia li sts i ntegra ted i nto the ma na ged menta l hea lth progra m c o  a ssure a ccess a nd conti nui ty of ca re; 
Member Services: Regi ona l customer servi ce centers affo rdi ng i nsta nt a ccess c o  eli gi bi li ty a nd clai ms i nforma ti on for qui ck a nd a ccura te response to member i nqui ri es. 
Specialty Networks: Occupa ti ona l in jury a nd hea lth ca re network s  speci fi­ca lly desi gned c o  control cose s a nd produce i mproved medi ca l outcomes; 
Disabil ity and Medical Case Management: Progra ms focused on ea rly return-c o- work pla nni ng a nd uti li za ti on revi ew of hi gh- cost ca ses; 
Claims Adjustment and Payment Review Systems: Fee revi ew systems a nd a clai ms a djustment process fully i ntegra ted wi th ma na ged ca re stra tegi es; 
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Health Care Information Services 
Value Health Sciences: 
Disease Management Programs and Clinical Review Services 
A signifi cant ch allenge facing managed care organizations, payers, and health care providers is improving quality and outcomes of care wh ile controlling cose s. 
Value Health Sciences (VHS) is a leading developer of sophisticated clinical soft­ware and provider review services which support medical decision making. VHS products and programs enable providers, third-party administrators, physician groups, HMOs, utilization review fi rms and employers to precertify medical, sur­gical, and diagnostic procedures, review claims to ide11 cify improper billing, iden­tify best practice patterns and outcomes of care, profi le providers, and provide comprehensive disease management. All services are designed to ensure medical­ly appropriate high- quality clinical practice and cost-effectiveness. In addition, VHS maintains a drug data base on 16 million lives involving the addition of 150,000 drug and diagnosis clai ms per year. The data base is used in drug out­comes research fo r  the FDA and pharmaceutical companies, and utilization review programs fo r  10 state Medicaid agencies. 
VHS has one of the largest and most ex perienced applied heal th services research teams in the man aged care industry, an d includes leading authorities in clinical medicine, utilization management, and info rmation systems. 
Lewin-VHI :  
Health Policy, Research, and Management Consulting 
Among the challenges facing both public and private sector organizations is how co improve th e health care system and how to respond proaccively and effective­ly co a ch anging marketplace. 
Lewin-VHI is the leading health policy and management consulting fi rm to chose inside and outside the government, offering ex pertise in corporate strate­gic planning and implementation, program and policy development, fi nancial and cost- effectiveness analysis, evaluation design, outcomes research, and microsimulation modeling. 
Our teams of nationally recognized professionals bring multidisciplinary skills, ex tensive fi eld ex perience, and expert use of sophisticated, in-house data bases and economic cools. These combine co help organizations rescrucrure or reeval­uate th eir operations in response to the economic and regulatory fo rces driving health care system ch ange. 
Value Health Management: 
Information and Management Solutions 
Purchasers face increased complex ity and management challenges in getting greater value from their health care programs. Starting with a cornerstone of comprehensive data anal ysis, Val ue Health Management (VHM) helps pur­chasers evaluate the perfo rmance of their programs. Combining sophisticated anal ytic tools with a fo cus on eval uating production processes, VHM deter­mines wh ere perfo rmance can be i mproved. 
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Medical Review System (MRS): An i nteracti ve, cli ni cally based expert system of practi ce gui deli nes chat prospecti vely determi nes the appropri ateness of select­ed hi gh- cost medi cal, surgi cal, an d di agnosti c procedures. MRS can be used on a stand- alone basi s, or i ntegrated wi th other uti li zati on management programs; 
Practice Review System (PRS): A fully i ntegrated, automated system chat appli es sophi sti cated cli ni cal logi c to analyze clai ms and ocher health data sources. PRS li nks data i nto cli ni cally meani ngful epi sodes of care and makes adjustments for severi ty and coexi sti ng i llnesses. PRS' prepayment modali ty analyzes and cor­rects or pends i ndi vi dual clai ms. Its postpayment modali ty produces profiles of provi ders, and networks for corporati ons. PRS also generates financi al and uti li zati on reports, and di sease and best practi ce profiles; 
Disease Management Services: Development of comprehensi ve programs char i mprove pati ent ou tcomes and control costs by organi zi ng managed care i ni­ti ati ves around di seases. A functi onal cli ni cal platform i s  i ntegrated wi th expert deci si on support, i ncorporati ng nati onal gui deli nes, expert judgment, and advanced case management techni ques. Programs can be tai lored to meet the speci fic needs of employers, managed care organi zati ons, and provi der groups. 
Public Health and Finance Policy: Poli cy analysi s, management consulti ng, program desi gn, mi crosi mulati on, and program evaluati on carri ed out for gov­ernment agenci es, foundati ons, purchasers, employers, communi ty- based orga­ni zati ons, and for i ndustry associ ati ons and professi onal soci eti es; 
Health Care Organizations: Consulti ng servi ces i ncludi ng mergers and affili ati ons, medi cal staff development, strategi c planni ng, and operati ons assess­ments provi ded to academi c medi cal centers, hospi tals and physi ci an groups; 
Economic Analysis: Economi c research and analysi s on health care, di sabi l­i ty, and labor economi cs i ssues for government agenci es (i ncludi ng health care programs sponsored by the Department of Defense), pri vate cli ents, and i nterest groups; 
Managed Care: Management consulti ng for publi c and pri vate payers, HMOs, hospi tals, provi ders, and i nvestors, offeri ng market analysi s, strategi c program desi gn, capi tati on rate setti ng, network contracti ng, acqui si ti on support, and i mplementati on; 
Medical Technology: Strategi c marketi ng studi es and evaluati ons of new medi cal technologi es, and rei mbursement for pharmaceuti cal and medi cal equi pment compani es, payers, regulators and associ ati ons. 
Integration of Health Information: Development of i ntegrated health care reporti ng systems to produce consi stent analysi s of health plan performance; 
"Out-Sourced" Supplier Management: Management of the li nkages between fragmented and complex purchasi ng arrangements, i ncludi ng measur­i ng performance agai nst agreed- upon targets, i mplementati on of new programs, establi shment and negoti ati on of suppli er contracts, coordi nati on of enrollment and problem resoluti on servi ces; 

































Blue Cross Blue Shi eld Plans Cedars-Si nai Medi cal Plan Communi ty Health Plan Group Health Plans Health Alli ance Plan Health Net Humana Independent Health Plan Intermountai n Health Care Plans 
AARP Ameri can College of Cardi ology Ameri can Hospi tal Associ ati on Bech Israel Hospi tal (Boston) Bri stol-Meyers Squi bb Catholi c Health Associ ati on Columbi a Presbyteri an Medi cal Center Connecti cut Department of Soci al Servi ces Department of Defense Department of Health & Human Servi ces 
Abbott Laboratori es Al li ed Si gnal Amoco Corporati on Amphenol Corporati on BellSouth Corporati on Commonwealth of Mass. Medi cai d Connecti cut Busi ness & Industry Associ ati on Harri s Corporati on Long Island Associ ati on Health Al li ance 
Wi lliam M. Mercer MetraHealch Paci ficare Health Systems Physi ci ans Health Servi ces Pri nci pal Fi nanci al Group Pri vate Healthcare Systems Provi dent Li fe & Acci dent Prudenti al 3M Health Informati on Systems 
Medtroni c Nae '[ Insti tute for Health 
I 
Care Management 
I New Mexi co Human Servi ces Department Pharmaceuti cal Partners for Better Healthcare State of Washi ngton Dept. of Health Texas Department of Health U ni versi ty Hospi tal Consorti um U CLA Medi cal Center W. Vi rgi ni a Publi c Employees Ins. Agency 
Occi dental Petroleum Procter & Gamble Promus Compani es Publi c Employees Reti re-ment System of Ohi o Stare Teachers Reti rement System of Ohi o U ni ted Technologi es Corporati on 
• The Walt Di sney Corporati on 
Depression 
1 994 Direct Costs: $ 1 6. l billion 
Depression affects 1 5  million to 
20 million Americans. 
Indirect costs due to morbidity 
and mortality total $40.6 billion. 
Asthma 
1 994 Direct Coses: $4.7 billion 
9 million to 12 million 
Americans are afflicted. 
5% of asthmatics account for 
70% of the costs of the disease. 
Indirect costs from morbidity and 
mortality contribute an additional 
$3.3 billion in costs. 
Disease management programs 
for asthmatics could produce a 
system-wide savings of 25%. 
Cardiovascular Disease 
(heart disease, stroke, 
hypertensive disease) 
1 994 Direct Costs: $ 1 1 0  billion 
56.5 million Americans have some 
form of cardiovascular disease. 
Two our of every five Americans 
die of cardiovascular disease. 
The indirect costs of cardiovascular 
disease total $ 1 8 .2 billion. 
Peptic Ulcer Disease 
1 994 Direct Costs: $3 .7 billion 
Nearly 6 million Americans are 
affected by peptic ulcer disease 
annually. 
Indirect costs from morbidity 
and mortality total $ 1 .2 billion 
annually. 
Cancer 
(excluding basal and 
squamous cell skin cancer 
and carcinoma in situ) 
1 994 Direct Costs: $35 billion 
1 ,208,000 new cancer cases 
and 538,000 deaths were 
projected for 1 994. 
Indirect costs from cancer mor­
bidity and mortality are estimate 
to coral $69 billion annually. 
Diabetes 
1 994 Direct Costs: $ 1 1 3 billion 
Approximately 1 1 . 1  million peo-1 
ple have diabetes (4.5% of the 
U.S.  population) . 
The 4.5% of the U.S. population 
with diabetes accounts for 1 4.6o/J 
of health care expenditures. 
Enrollment in Medicare's End 
Stage Renal Disease (ESRD) pru­
gram has grown dramatically pri­
marily due to older individuals 
and people with diabetes. 
Benign Prostatic 
Hyperplasia (BPH) 
1 994 Direct Costs: $4 billion 
14 million older men suffer fro 
symptoms related to BPH. 
An estimated one in every four 
men in the U.S.  will be treated 
for relief of symptomatic BPH 
by age 80. 
Prostate surgery (TURP) is the 
second most common surgical 
procedure performed in the 
Medicare population, second 
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alue Health:  Bringing Science to 
the Art of Managed Care . . .  Disease by Disease 
"Disease management" is a hot new topic in health care. At 
Value Health, we chink it isn't just a fad, but an important, 
improved way of approaching health care - and managed care. 
So important, in fact, that we're devoting this part of the annual 
report co discussing this new concept. But just what is meant by 
"disease management"? How is it different from what's been 
done before? Why is it important? What are the cools needed co 
deliver disease management? And what makes Value Health's 
approach different? Lee's answer the most obvious question first. 
Defining Disease Management 
There are a lot of definitions appearing around the concept of 
disease management. Often, they vary with the interests and 
perspectives of the user. At Value Health, we're trying to keep it 
simple. To us, disease management means taking a comprehensive, 
systematic approach to improving patient outcomes and lowering 
costs in key disease categories. Outcomes are the results achieved 
through a particular health care service. Desired outcomes 
include improved patient functionaliry, health status, satisfac­
tion, and lowered costs of treatment. 
We'll admit that probably doesn't sound revolutionary, but 
in fact it's quite different from how managed care is organized 
today. Managed care traditionally hasn't focused on diseases. It 
has instead measured its success in terms of input categories -
often referred co as "component management." So, managed 
care experts pour over data "inputs" such as hospital admission 
rates, length of hospital stays, hospital days per thousand mem­
bers, outpatient visits per thousand, per-member-per-month pre­
scription drug costs, or Cesarean section races. Moreover, the 
major premise of most HM Os is co avoid the use of specialists in 
favor of primary care generalists and gatekeepers. And yet, the 
sickest 5% of the population who in fact generate 60% of health 
care costs are typically beyond the care of primary care physi­
cians alone. They need specialty care - and specialized disease 
management. 
By and large, managed care hasn't yet concerned itself with, 
for example, how to improve cancer care in terms of specific 
patient outcomes - a disease management approach. This is, co 
us, the next frontier, or as one managed care CEO put it, "the 
holy grail" of health care as it relates co both cost and quality. 
Why Is Disease Management Important? 
In terms of coses, disease management aims squarely at the major 
concentrations of health care expense. As mentioned earlier, 
in any year, 5% of the population accounts for 60% of health 
care claims costs. By contrast, 50% of people generate only 3% 
of claims costs. The David graphic at the left helps illustrate this 
important point still further. The big expenditures are 
inevitably with very sick people - these patients have chronic 
and acute diseases. So - disease management is important 
because it's where the greatest opportunity for improvement 
and savings resides. 
In quality terms, outcomes-based disease management 
would give patients a whole new basis for choosing health plans 
and providers. Imagine being able to obtain severity-adjusted 
comparative data on real patient outcomes versus simply choos­
ing your health plan based on cost and a physician list. Think 
what that would do co raise the level of quality competition in 
health care! 
Simply stated, successfully managing the costliest disease 
states will have a profoundly positive effect on health care as 
we know it. 
"Targeting and monitoring at-risk patients 
for prevention and treatment is far more 
efficient than offering population-wide 
effo ftS . "  Mark Zitcer, President, The Zitrer Group, San Francisco 
How to Expand? Go Where the Opportunity Is.  
5% of the population incurs 
60% of health care claims 
50% of the population incurs 
3% of health care claims 
Health Care Spending 
c; 
e . 
$ 1  Tri l l ion in U.S. Health Care Spending 
Direct Health Care Costs for Key 








Disease $ 1 1 0  billion 





$ 1 1 3  billion 
Benign Prostatic 
Hyperplasia $4 billion 
Value Health managers have been pioneers in managed 
care for over 20 years - long before the concept was 
even cal led "managed care." We believe the experi­
ence of our staff is unparal leled in our business, having 
attracted industry leaders from major managed care 
companies such as CIGNA, Kaiser Permanente, Aetna, 
MetraHealth (formerly Travelers and Metropolitan), 
United HealthCare, and Blue Cross Blue Shield plans. 
We've also drawn talented managers from leading 
health care product companies such as Merck, 
McKesson, and Baxter, benefits managers from Fleet, 
GE, and New York State, and researchers and analysts 
from RAND, UCLA, and federal and state agencies. 
From private practice physicians to successful senior 
managers, entrepreneurs to academicians, Value Health 
executives have been - and continue to be - at the fore­
front of managed care. 
"Value Health's management team has the strength and 
breadth to successful ly develop programs for new mar­
ket sectors, especially in the area of disease manage­
ment. They're one of the few companies positioned to 
do this - with the people, systems and programs to 
bring health care into the next century." Sara A. Fisher, 
Equity Analyst, Vice President, UBS Securities 
Value Health: Bringing Science to the 
Art of Managed Care 
Moving into disease management allows Value Health to evolve 





prescription drugs, and into the entire medical-surgical field - hec 
affecting the greatest areas of cost and affording the most signifi­
cant impact on outcomes. 
For Value Health, disease management offers particularly 




been pioneering for years. We were founded in 1987 with the What ) 
objective - expressed in our tag line - of "bringing science to the From Ol 
art of managed care." By that phrase we meant that we wanted ment re< 
to focus on identifying and reducing medically inappropriate like case 
care, rather than aiming just at provider discounts or reduced 
hospital days. We determined that we had to focus on clinical 
issues, and that required organizing managed care around the 
same specialry categories that health care itself had developed -
for example, mental health care. So, the business of "specialry 
managed care" was born. At the same time, we learned that we 
needed new information-based technologies - the ability to 
develop and apply clinical protocols, to measure and influence 
physician practice patterns, and to screen medical claims records 
to identify changing patient outcomes. 
Our combined specialry managed care and information 
services technologies are described in the fold-out section pre­
ceding this essay. These programs have worked well for our cus­
tomers, reducing costs by 10% to 50% as measured against 
unmanaged benefits. As important, outcomes analyses and 
member surveys indicate high levels of satisfaction and better 
health outcomes. 
With this proven track record as our foundation, we find 
disease management to be a natural extension of our existing 
Value Health capabilities. 
"Value Health has had a dual focus on quality and 
cost management from our beginning - that's what 
we meant by putting 'value' in our name. We're 
pleased to now find that the two broad areas in whid 
we've been involved - specialty managed care tools 
and health care information services - are the key 
building blocks for disease management. Disease 
management is a natural  evolution for us . . .  and an 
important addition to our product l ine." 
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"Quality information wil l  play an ever-increasing and 
vital  role in integr ating health care delivery systems, 
making positive changes in physician practices, and in 
helping employees and their dependents make informed 
health care decisions. Va lue Health's clinically based 
information capabil ities make them qualified to be a 
leading catalyst for these important changes." 
Glen E. Cline, Senior Vice President, The Sega l  Company 
What Are the Tools of Disease Management? 
From our exper ience to date, we've learned that disease manage­
ment requires the customizing of known managed care tools -
like case management, network management, clinical protocols, 
practice guidelines, provider profiling, and patient education 
materials - and the need to build new tools, in such areas as the 
measurement of outcomes. 
O ur comprehensive concept of disease management encom­
passes analysis, planning, and i ntegration of all factors required 
to diagnose, treat, and monitor a patient's disease over its full 
course. Disease management requires a continuum of care. 
Episodes of illness ar e reviewed, treated and managed as p;trr of 
a continuum of the disease. Tools are designed to: 
aid in more efficient and earlier diagnoses by physicians; 
improve treatment through practice guidelines; 
i ntegrate treatment p rograms among all caregivers 
through case management; 
provide patient education and compl ian ce programs ; 
i nstitute sys tems to make care mo re pleasant fo r  
patients and their families ; and 
demonstrate the value crea ted thro ugh ou tcomes 
meas urement. 
Cus tomized disease management programs will have unique 
,a t' s wha t 
I 
se�s of interven.tions in the . diagnose� and treatment proce�ses , We're tailored therapies for the different disease s tages, and speoal 
reas in wh ich tracking and reporting sys tems to assess and measure outcomes, 
I ca re tools and identify patterns . Programs are matched to physicians ' work 
� the key flows to ass ure accep tance and appro priate use. And proper 
Disease incentives are developed that match the particular provider of 
_ _  . and an care. We seek to assess the effectiveness of treatment programs 
review teams 
cost procedures - balancing ri 
benefits. Direct savings: $500 per case revi 
Practice Review System (PRS) : assists network man­
agers and medical directors in maintaining network 
quality by profiling provider practice patterns. PRS 
enables us to measure the costs of providing care for 
a disease as well as identify the best practice patterns 
and the providers who use them. PRS incorparales 
over 1 800 diagnostic categories with severity and 
comorbidity adjustments. 
Outcomes Management Systems: customized and 
comprehensive retrospective and real-time systems 
developed to determine if disease management pro· 
gra ms achieve their goals. There a re five key compo­
nents in assessing outcomes: 
■ impacts on cost and utilization; 
■ patient and provider satisfaction; 
■ im pacts on functional st atus, that is, the ability 
to perform the functions of daily l ife; 
■ process of ca re evaluations; and 
■ patient clinical outcomes, such as morbidity 
a nd mortality. 
" When you look into P RS and see 
what drives the clinical engine , it has 
no competitors . Quite simply - it 's 
the most clinically advanced system 
in the industry. " 
Jim Cross, M.D., Senio
r Vice President and National Medical Director, MeuaHealth 
as they unfold, and continuously refine and improve them to 
ensure that the best care is provided. Our disease management 
programs strengthen the link between physicians and patients -
an important change from component management that ofren 
causes managed care techniques be an unwelcome wedge in 
this relationship. 
How Is Disease Management Delivered? 
There are several ways to effectively deliver disease management 
programs to reduce cost inefficiencies while improving treatment 
and outcomes. All of these delivery systems can be offered either 
on a fee or a risk-sharing basis. 
Delivering Disease Management as a Carve-Out 
There are certain diseases that are managed mostly by physicians 
in a single subspecialty rather than being handled by a 
range of primary care and specialist doctors. In these areas, 
it's possible to "carve out" the management of the disease 
from a general provider network and to substitute a specialty 
program and network organized around disease management 
principles. So, employers, insurers and health plans can, in 
effect, subcontract the care for a particular group of patients 
to a specialty program. 
This is what Value Health does now, in the disease area of 
mental health, for example. 
In 1993, Value Behavioral Health (VBH) was created. We 
combined two of the nation's leading mental health manage­
ment companies, the former American PsychManagement (a 
Value Health company since 1987) and the former Preferred 
Health Care, both founded in 1983, to create the nation's largest 
behavioral health company. VBH provides our mental health, 
substance abuse, and employee assistance programs and has 
been a laboratory for formulating our disease management tech­
nology. By carving out mental illness from mainstream benefits, 
Value Health has been able to develop specialized techniques to 
reduce overall mental health costs and provide more appropriate 
treatments for mental illness. And the results speak for them­
selves as the chart on the next page - with results from just one 
of our nearly 1000 customers - helps show. 
"Despite all of the evolutionary changes 
in managed care, one fundamental prin­
ciple remains constant: Physicians have 
responsibility for their patients' quality 
of care. So, physicians' willingness to 
adopt new disease management 
approaches will directly relate to their 
confidence that the programs can 
. . " improve care - not JUSt save money. 
Robert W. Dubois, M.D. ,  Ph.D. ,  Execurive Vice Presidem and Chief Medical 
Officer, Value Heakh Sciences 
"I believe that Value Health is extraordinarily well po! i­
tioned to develop disease management programs. I 
expect that the company wil l  leverage their experiencci 
in managing specialty carve-out niches, their expertisE 
in developing cl inically driven information systems, ard  
the strength of  their management team, clinical staff, 
and extensive data bases to create industry-leading 
disease management programs." 
Eleanor H. Kerns, CFA, Principal,  Alex. Brown & Sons 
Mental Health and Substance Abuse in the U.S. 
$85 bil lion spent on direct mental health 
care in 1 994. 
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Here are some examples of how general managed care tech­
ques are changed and customized to a specific disease manage­
'ent program in the mental health field: 
patient access: instead of relying on published provider 
directories, patients gain access through employer-based 
Employee Assistance Programs (EAPs) or 24-hour toll-free 
telephone "help" lines; 
gatekeeping: assigning primary care gatekeepers ahead of 
time wouldn't work since most members don't have a cur­
rent mental health need. Rather, members call a telephone 
help line to access care; trained clinicians triage the case to 
the most appropriate rype of provider; 
patient treatment plans: given the lack of continuity of 
care and the absence of clear objectives which often prevail 
in mental health treatment, VBH uses trained clinicians as 
case managers to work with treating therapists to coordinate 
care and to develop clear treatment plans; 
case management: given the importance of avoiding 
unnecessary hospitalizations arising from emergency 
room visits, psychiatrists are contracted to be on call 24 
hours a day to go to emergency rooms to assess patient 
severity. Typical telephone prior approval wouldn't work 
in such situations; 
clinical protocols: VBH uses the mental health review 
system developed in collaboration with Value Health 
Sciences plus a widely distributed Clinical Procedures 
Manual to improve practice patterns among its providers; 
provider profiling: criteria specific to mental health and 
substance abuse treatment have been used to develop soft­
ware which profiles provider practice patterns to identify 
those to whom referrals should be preferentially directed. 
In the sense that mental health management can be consid­
red a precursor to disease management, we've been at it for 
ore than 10 years - since the inception of our predecessor 
ompanies. We organized our specialized managed care tools, 
iterventions, and resulting data around the diseases of mental 
ealth and substance abuse. That's why we consider our 
ecialty mental health management to be the best example 
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In the two years VBH has managed the program for this 
customer, total direct savings of $52 million have been 
realized. And these savings were achieved with less 
than a 2% member appeals rate. 
We decreased client costs by more than 50% while 
increasing the benefit level to 1 00% for in-network ser­
vices and improving member access. 
Clinical  Groups: Partners with Providers 
in Managed Mental Health 
" I participate in some capacity on over 50 mental  
health panels and I think VBH is c learly the best in the 
business - always ahead of the pack, doing things now 
that you can be sure others wil l  try to follow in the 
future. Clinical Groups are an example. 
As a part of VBH's Anchor Group concept for 
six or seven years providing inpatient and substance 
abuse treahnents, I feel we've been a partner in the 
ongoing evolution to VBH' s Cl inical Group (CG) concept 
where now outpatient treahnents are also included. 
VBH understands that the effective management 
of the disease takes into account all aspects on the 
care continuum. 
To the patient, that means much better coordina­
tion of care throughout treahnent. They're involved in 
their plan from the start - it's focused and goal driven. 
They get the right care at the right time by the right 
provider. And they're able to self-refer within the CG -
eliminating things l ike precertification and paperwork 
often associated with managed care. 
To employers, it means better functioning employ­
ees and dependents, and controlled costs because CG 
treahnent plans look at all aspects - EAPs, community 
resources, 1 2-step programs, inpatient and alternative 
care facil ities, psychotropic medications, primary care 
physicians . • •  multiple factors. 
To us as care providers, CGs bring a welcomed 
discipline to clinically based quality standards second 
to none - developed, monitored, and constantly 
improved by peer review. This translates into 
improved services, clinical skills, treatment planning, 
util ization of community resources - and results. 
There's an added value: As a CG participant, we're 
recognized as better care givers because of our unpar­
al leled quality initiatives." Morris Gelbart, Ph.D., Clinical Director 
and Principal ,  PsychCare Alliance, Redondo Beach, CA 
" A lot of mental health practitioners - and patients -
have a "mythical" fear of managed care, thinking it's 
adversarial .  With Clinical Groups, nothing could be 
further from the truth. Our group of 60 practitioners 
represents a wide range of discip l ines and clinical 
expertise. As partners with VBH, our mutual dedica­
tion to effective management of the disease of mental 
i l lness for better outcomes gives us a singularity of 
purpose." Peter B. Hirsch, M.D., Ph.D., Medical Director and Principal, 
PsychCare Alliance, Redondo Beach, CA 
And it's also just one of the reasons why we consider Value 
Health to be uniquely qualified - from both experience and 
strategic planning perspectives - to successfully develop and 
implement comprehensive disease management carve-outs. 
In the area of a cancer carve-out, Value Health Sciences 
(VHS) recently completed, for one of the nation's leading cancer 
treatment centers, the first in a series of guidelines focusing on 
the use of bone marrow transplantation in breast cancer treat­
ment. VHS also looked at the site of cancer chemotherapy and 
use of antiemetics, each to be the subject of future guidelines in  
our cancer disease management series. 
The resulting guidelines are based on the methodology first 
developed by the RAND Corporation that uses the collective 
judgments of internationally known academic and clinical 
experts to produce consensus-based protocols. This methodolo­
gy was integrated with sophisticated statistical techniques to 
develop guidelines for the use of bone marrow transplantation 
covering more than 1200 patient categories. 
Delivering Disease Management as a Carve-In 
A "carve-in" is a program which provides tools to a managed 














cians, rather than substituting a different specialty network. This excess of : 
will be the case for diseases where treatments are provided by a 
range of primary care physicians and/or specialists rather than by 
a single subspecialty. Diabetes is an example of a disease likely 





adult blindness, cardiovascular disease, and amputations involve comes me 
virtually the complete spectrum of internal medicine. Value 
The most significant cost savings can occur through the p re· carve-in tc 
vention of emergency hospitalizations for diabetes with acute health sen 
blood-related complications, such as diabetic ketoacidosis do disease 
(DKA) and hyperosmolar coma. Our diabetes disease manage-
ment program will target reducing and preventing hospitaliza-
tions through: 
more aggressive metabolic targets for better control; 
blood pressure control; 
lipid (cholesterol) management; 
patient self-management and compliance with approved 
medical regimen; and 
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The American Diabetes Association (ADA) has indicated 
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:o a managed 
: existing physi 
lty network. T 
: provided by a 
sts rather than 
sting annually. They also state that tight controls could reduce 
ospiralizations from complications between 45% and 60%, or 
erween $17 billion and $23 billion annually. 
Value Health case examples reveal potential savings of 70% 
� hospitalization costs alone which is actually more than that 
·edicted by the ADA. And, analyses of customer data on 
arients with diabetes show that overall savings can average in 
;xcess of 20% following the implementation of proposed Value 
ealth diabetes disease management programs. 
The tools of a carve-in program include specialized case 
a disease likely anagemenr, provider and patient education programs, clinical 
cations such as rotocols and pathways, specialized utilization review and out-
1utations invol omes measurement programs. 
.rcme. Value Health has substantial experience in developing 
· through the p arve-in tools. VHS and Lewin-VHI - our clinical, analytic and 




o disease management as no other company can. VHS creates 
clinical software tools like MRS and PRS, discussed on page 13, 
which it sells to HMOs, insurers, and group practices, among 
others. And Lewin-VHI has worked over the years with a wide 
range of physician specialty societies and provider groups on 
disease management systems. 
Delivering Disease Management as a Provider 
Another means of delivering disease management programs is by 
being the direct medical provider - rather than the network 
operator - presumably acting as a preferred provider to an 
employer or health plan. We're already seeing this development 
in the market as specialty provider-based disease management 
organizations have sprung up in such areas as medical oncology, 
hemophilia, and diabetes. Specialty provider management or 
ownership is a possible direction for Value Health as we deepen 
our engagement in disease management. 
Delivering Disease Management as a Pharmacy 
Benefit Manager 
The addition of customized programs as part of the prescription 
drug benefit offered by PBMs such as ValueRx is another deliv­
ery vehicle for disease management. 
Asthma is a likely candidate for this scenario. The proper 
use of asthma medicine can help patients avoid expensive emer­
gency treatments and hospital stays. ValueRx offers targeted 
programs that our customers use to educate their asthmatics on 
proper use of medication, and, importantly, the steps to take 
before the onset of a major attack to avoid hospitalization. 
Through our data analysis capabilities, we can identify patients 
who seem to be experiencing unnecessary emergency room visits, 
and begin the process of counseling and educating them to avoid 
costly services. 
ontrol; 
elect research of diabetes disease management programs shows large cost savings can result from reductions in chronic 
omplications, including up to a: 
h approved 
complications. 
50% reduction in lower extremity amputations by implementing education, hypertension, 
and glycemic controls; 
70% reduction in episodes of ketoacidosis through better education and further glycemic c,tntr, 
50% reduction in End Stage Renal Disease (ESRD) cases through appropriate control of h 
60% reduction in diabetes-caused blindness by improving education and use of early 
nd still further savings can be accrued in occupational productivity improvements, including 





ValueRx provides extensive patient and provider education 
now as it relates to drugs and prescribing patterns, covering over 
8.5 million people with drug utilization review designed to avoid 
adverse reactions. 
Our experience supports findings that up to 40% of pre­
scription drug use is inappropriate. That problem is particularly 
acute among the elderly, where 25% of people aged 65 or older 
are prescribed a potentially inappropriate medication, according 
to The Journal of the American Medical Association. Value 
Health's detailed follow-up assessments have shown our program 
resulcs in changes in drug therapy producing plan cost savings 
and improved healch outcomes for patients in 65% of all our 
cases. And we're continuously developing more effective pro­
grams and interventions, focusing on about 20 of the most 
promising disease areas. 
Value Health and the Pharmaceutical Industry: 
Partnering for Success 
To capitalize on the opportunities present in disease manage­
ment, Value Health is pursuing a variety of strategies. One 
is to form strategic alliances with leading pharmaceutical 
man ufaccurers. 
"Pharma companies," as they're called, share our interest 
in disease management. It's viewed by them as an opportunity 
for strategic diversification into health care services, often in cat­
egories where they have a drug or medical/surgical device inter­
est. Disease management leverages both the pharma companies' 
extensive knowledge of the science of the disease and its field 
forces for use in educational programs with physicians. As 
important, the companies have a culcure of research and devel­
opment, as well as a tradition of interest in outcomes forced 
by the need to measure and prove efficacy to the U.S. Food and 
Drug Administration. 
Value Health has extensive experience in chis area as well. 
We maintain a data base of over 16 million active patient lives, 
involving over 150 million drug and diagnosis claims inputs per 
year. Our data base is used in outcomes, efficacy, epidemiologi­
cal, and scientific analyses performed for the FDA, making 
Value Health one of their leading non-academic advisers. The 
data is also used for research by the nation's leading pharmaceu­
tical manufacturers. 
"Value Health goes deeper than PBMs ca 
into the medical end of disease manage­
ment, with its various companies - like 
Value Health Sciences - developing prac­
tice guidelines and providing extensive 
utilization review." 
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The entire population of caregivers - pt,ys· 
nurses, pharmacists, clinicians, hospitals and 
other care facilities - must be includcict. 
It's vital to address the complete nature of the 
illness - acute phases, remission, recurrences, 
maintenance, and cure. 
Programs must identify and address the key junc· 
tures or levers in the provision of care where best 
practices can significantly affect patient outcomes. 
At Value Health, we focus on how to justify and 
uantify - in advance - the benefits of such a program. 
hen we develop the clinical management systems, or 
eries of tools, that enable the provision of the best care 
·or the disease. Such systems include diagnostic aids, 
everity of illness stratification, practice guidelines, 
rovider and patient education, and case management. 
.ast, we use a comprehensive - and proprietary - set of 
utcome assessment tools, including cost and utilization 
ata, patient and provider satisfaction surveys, function­
I status, intermediate outcomes throughout the cycle of 
are, and morbidity and mortality measures. 
The result: Value Health can effectively develop dis­
ase management programs that help individual care­
ivers understand the care that they can provide, 
emonstrate to managed care entities the value of the 




ontrolling costs, and improve patient outcomes . . .  
isease by disease. 
'We believe that the development of disease 
anagement programs allows us to capitalize 
n all of our prior experience in specialty 
anaged care and information management 
n health care. It's a wonderful confluence of 
here we've been and where the managed 
are and pharmaceutical worlds are going." 
obert E. P Ii ( airman and CEO, Value Health 
"Pfizer research has given us unparalleled knowledge 
of diseases and world-class medicines to treat them. 
Value Health is a leader in translating that knowledge 
into therapeutic regimens that achieve the best patient 
outcomes and demonstrate the cost-effectiveness of high­
quality therapies to managed care customers. This is a 
highly complementary fit." Edward C. Bessey, Vice Chairman, 
Pfizer Inc and President, U.S. Pharmaceuticals Group 
Value Health and Pfizer 
Our first alliance, forged in 1994, is a two-part agreement with 
Pfizer Inc, a world-renowned pharmaceutical company. 
Under the first agreement, Pfizer entered into a multi-year 
contract with Value Health to develop value-added programs 
designed to improve physician and patient use of Pfizer pharma­
ceutical and medical device produces, as well as a series of disease 
management programs chat aren't necessarily linked to drugs or 
devices. These programs include many of the kinds of technolo­
gies we've addressed throughout chis report - clinical protocols 
for drug and medical therapy, physician and education materials, 
and outcomes analyses. 
The second agreement is a 50-50 joint venture partnership 
with Pfizer to develop network-based disease management carve­
out programs. This new company, called Disease Management 
Sciences, has an initial committed capitalization of $100 million, 
funded equally by the two partners. 
We intend to build on the pattern of our arrangement 
with Pfizer and develop more strategic alliances with 
major drug companies as we seek to develop and implement 
disease management. 
Bringing Science to the Art of Managed Care . . .  
Disease by Disease 
In managed care, no one programmatic approach is a panacea -
but disease management will be an important part of the arsenal. 
And at Value Health, disease management represents an impor­
tant third leg of our managed care stool, along with specialty 
benefits and health care information services. 
Disease management is a new way of chinking about man­
aged care. A way focused on outcomes - and that's good news 
for patients and consumers. 
Value Health continues our evolutionary approach to better 
managing health care quality and costs by seeking to bring sci­








Value Health: Bringing Science to 
the Art of Managed Care . . .  Disease by Disease 
Summary 
We've spent a good deal of time explaining our definition of and 
plans for disease management. We realize that there are terms 
and concepts with which you may not be familiar. So, we've 
provided a glossary of some of the most commonly used terms 
related to this concept. We hope it's helpful. And we hope 
we've successfully answered the questions we set forth at the start 
of this report. To summarize: 
What is disease management? A comprehensive, systematic 
approach to improving patient outcomes and lowering costs in 
key disease categories by customizing managed care tools in a 
variety of program packages that can be sold for fees or on a risk­
sharing basis. 
Why is it important? Because the major diseases are where the 
money is in health care; it's where the major opportunities are to 
improve quality and reduce costs. 
How is it different from the past? Managed care has tradition­
ally organized around components or input categories of treat­
ment; it hasn't focused on outcomes measurement. In addition 
to organizing the components around diseases, improved out­
comes will be the focus of Value Health disease management 
programs. 
What is the Value Health difference? Our experience in dis­
ease management in the mental health, data and program analy­
sis, and clinical protocol fields. No other company has our com­
bination of capabilities, battery of tools, and staff of industry 



































Capitation - a method of payment for providers or health plans. 
A primary care physician or a health plan is paid a fixed rate (or capitated fee) per month for certain defined care needs of a cov­ered patient. Shifting the risk and melding finance and delivery are intended to stimulate preventive care and promote appropri­
ate use of the delivery system. 
Carve-in - applying specialized tools within a managed care or 
provider organization to be used with existing physicians. 
,, Carve-out - a specialty network-based program designed to manage care of a disease that can be segregated from general 
benefit or treatment programs. 
Clinical management protocols - guidelines developed from 
literature and consensus judgment aimed at determining the appropriateness of proposed procedures to support medical 
decision making. 
Comorbidity - existence of more than one disease or the coexis­
nce of disease symptoms. 
Disease management - a comprehensive, systematic approach 
to improving patient outcomes and lowering costs in key 
isease categories. 
Drug Util ization Review (DUR) - series of programs and com­
::ruter-based analysis tools designed to provide a quantitative valuation to pr�mote clinically appropriate and cost-effective 
rescribing, dispensing and use of prescription medications. 
' 
URbase™ - ValueRx's proprietary computerized drug claims eview system that identifies people at risk for drug-induced 
llnesses; DURbase™ is the nation's largest retrospective outpa­ient-focused DUR program. 
ormulary - a listing of preferred prescription medications 
nd prescribing guidelines which is regularly reviewed and pdated. An "open or voluntary" formulary allows coverage or both formulary and non-formulary medications. A "closed, elect or mandatory" formulary limits coverage to just those 
, rugs in the formulary. 
atekeeper - point of contact through which members receive dditional care or referral. 
Managed fee-for-service - the cost of covered services is paid 
by the insurer after services have been received. Various managed care tools such as precertification, second surgical opinion, and 
utilization review are used. 
Multispecialty medical practice - a group practice that provides a broad range of medical services through an affiliated practice 
of physicians that ranges from primary care physicians to highly 
focused specialists (e.g . ,  cardiologists) . 
Outcomes - results achieved through a particular health care 
service; desired outcomes include improved functionality, 
health status, satisfaction, and lowered costs of treatment. 
Outcomes management - systematically improving 
health care results, typically by modifying practices in 
response to data gleaned through outcomes measurement, 
then remeasuring and remodifying in a formal program of 
continuous quality improvement. 
Pharmaceutical (or Prescription) Benefit Managers (PBM) -
organizations that manage pharmaceutical benefits for the payer 
(self-funded employers, insurance companies, PPOs, HMOs) . 
They provide many services designed to lower pharmaceutical 
costs for their clients, including: claims processing, developing pharmacy networks , negotiating pharmacy fees, formulary and 
generic substitution programs, and outcomes analysis . They also 
monitor physician and patient prescribing and provide physician education on appropriate drug use. 
Primary Care Physicians (PCPs) - a group of physicians who 
care for the fundamental health care needs of a patient popula­tion. The following are generally considered primary care disci­
plines: internal medicine; family/general practice; and pediatrics . Obstetricians and gynecologists also can be considered primary 
care physicians. 
Provider profiling - reviewing and comparing practice patterns among physicians or health plans based on criteria having to do 
with cost, utilization, quality, and patient satisfaction. 
Risk-sharing agreements - compensation arrangements 
between payers and health plans, or health plans and providers, 
whereby the financial risks and benefits of higher or lower 
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anagement's Discussion and Analysis of Financial 
Condition and Results of Operations 
Overview 
Value Health, Inc. ("the Company") is a leading provider of 
specialty managed health care benefit programs and health care 
information services. 
On August 29, 1994, the Company completed its merger with 
Prescription Drug Service, Inc., based in Hauppauge, New York, 
and its affiliated company Prescription Drug Service West, Inc. 
(collectively, "PrescDrug"), based in Chandler, Arizona. The 
Company issued 937,178 shares of its common stock in exchange 
for all of the outstanding common stock of PrescDrug. The 
PrescDrug companies are suppliers of mail service and retail 
prescription drug benefits to national, regional and local union, 
corporate and HMO benefit plans. 
On August 31, 1994, the Company acquired by merger all of the 
outstanding common stock of RxNet, Inc. ("RxNet''.) by issuing 
256,136 shares of its common stock for all of the outstanding com­










Costs of services 
Selling, general and administrative 
Depreciation and amortization 
Interest expense 
Merger-related expense 
T oral expenses 
Earnings from continuing operations 
before income taxes 
Provision for income taxes 
Earnings from continuing operations 
offers prescription drug card programs to insurers, self-insured 
employer groups, third party administrators, and multiple 
employers trusts and associations. 
Both of these transactions have been accounted for as poolings of 
interests and financial statements for all periods prior to these com­
binations have been restated to reflect the combined operations. 
1994 revenues of $976.4 million increased $286.9 million or 
41.6% over 1993, and 1993 revenues were $689.5 million or 
88.6% ahead of 1992. The Company had earnings from continu­
ing operations before income taxes (excluding merger-related 
expense) of $88.6 million for 1994, compared to $56.1 million in 
1993, and $27.4 million in 1992. 
Results of Operations - Continuing Operations 
The following table sets forth certain consolidated financial data as 
percentages of total revenues for the three fiscal years ended 
December 31, and the percentage changes in the dollar amounts of 
revenues and expenses for 1994 as compared to 1993 and for 1993 
as compared to 1992. 
Percentage of Revenues 
for the yea r ended December 3 1 ,  
1994 1993 1992 
67.0% 63.8% 61.7% 
20.3 23.4 31.2 
6.9 5.2 0.4 
4.2 5.4 3.4 
1 .0 1.1 1.7 
0.6 1.1 1.6 
100.0 100.0 100.0 
78.2 78.4 77.8 
10.6 11.3 12.3 
2.0 2.0 2.2 
0. 1 0.1 0.2 
0.6 5.6 -
91 .5 97.4 92.5 
8.5 2.6 7.5 
3.4 1.6 2.2 
5. 1% 1.0% 5.3% 





































Years Ended December 31 , 1 994, 1 993 and 1 992 -
Continuing Operations 
Total revenues increased by $286.9 million in 1994 over 1993 and $323 . 8  million in 1993 over 1992. Existing customers produced $64.6 million and $39 .5  million, respectively, of 1994 and 1993 revenue growth. Revenues from new customers grew by $177 .1 million in 1994 over 1993 and $197. 8  million in 1993 over 1992. Acquisitions accounted for $45 .0  million and $84 . 5  million, respectively of 1994 and 199 3 revenue growth. 
Prescription drug revenues for 1994 of $654.4 million increased by $214.6 million or 48 .8% over 1993, and 1993 revenues increased by $214.4 million or 95 .1 % over 1992. Of these increases, $73 .0  million and $34.2 million, respectively, were asso­ciated with existing customers and resulted primarily from the addition of covered lives by current V alueFee customers and, in 1994, the expansion of the Ford contract. Approximately $136 .8  million and $144.2 million, respectively, were associated with the addition of new customer accounts, primarily in the Company's ValueFee business .  
Mental health and substance abuse 1994 revenues of $198.6 million increased by $37.0 million or 22.9% over 1993, and 1993 revenues of $161.6 million were $47.4 million or 41. 5% higher than in 1992. Of these increases, $31.3 million and $43 . 7 million, respectively, resulted from new business. Revenue from existing customers in 1994 declined by $4.9 million over 1993 primarily due to changes in product selection by customers, from risk-based to administrative services only contracts . Revenue from existing customers in 1993 increased by $3 .2 million over 1992. 
Insurance services 1994 revenues of $67.3 million increased by $31.4 million or 87.4% over 1993 and 1993 revenues of $35 .9 million increased by $34 . 5  million over 1992. Of the 1994 increase, $6.1 million was due to the addition of new customers and $29.3 million was due to the acquisition of Community Care Network, Inc. ("CCN") in June, 1994. Revenues from existing customers declined by $4.0 million in 1994 over 1993 primarily due to customer losses and enrollment reductions. Of the 1993 increase, $32.3 million resulted from the acquisitions of Adjustco, Inc. and Diversified Medical Resources, Inc. in December, 1992. 
Information services 1994 revenues of $40. 7 million increased by $3 .8  million or 10.4% over 1993 and 1993 revenues of $36.9 million increased by $24.2 million or 190.1 % over 1992. New customers produced $2.9 million and $7.1 million, respectively, of 1994 and 1993 revenue growth. Of the remaining 1994 increase, $ .4 million was due to acquisitions and $ . 5  million was due to existing customers. The remainder of the 1993 increase was primarily due to the acquisition of Lewin-VHI, Inc. in December, 1992. 
Other revenues in 1994 of $9.7 million increased by $2.3 million or 31.0% over 1993 in which revenues were $7.4 million or 
21 .0% higher than 1992. The increases in both years were due to additional covered lives in podiatric benefit programs. In addition, the 1994 increase is due to the sale by the Company of an option on its 5 .4% interest in Health Spring, Inc. ("HSI") (see note 2) . 
Investment income in 1994 of $5 .7  million was $2.1 million or 26.8% lower than 1993 revenue which was $2.1 million or 36.3% higher than 1992 revenue. The decrease in 1994 was due to lower investment balances resulting from acquisitions completed and the shift to tax-advantaged investments during the third quarter of 1993, which carry lower interest rates. The increase in 1993 was due to higher investment balances resulting from the Company's 1992 stock offerings and from operating cash flow. 
The Company's costs of services consist of direct expenses of pro­viding specialty managed care and information services, including costs of prescription drugs, mental health and substance abuse provider charges, foot care provider charges, salaries and wages of medical management and health policy consultants, customer ser­vice and claims processing personnel, and certain data processing costs. Costs of services for 1994 increased $222.9 million or 41.2% over 1993, and 1993 costs were $256.2 million or 90.0% greater than in 1992. Most of these increases were due to an increased number of plan participants and provider and drug price increases . As a percentage of revenues, costs of services decreased to 78 .2% for 1994, from 78.4% in 1993 and 77.8% in 1992 . In both 1994 and 1993 the mix of business shifted from mental health to prescription drugs, causing the cost of services percentage to increase. The 1994 decrease in this percentage was caused by the acquisition of CCN, which carries a lower cost of services ratio. During 1993 and 1994, the Company experienced significant price competition in the prescription drug business .  In response, the Company undertook more aggressive pricing policies and also entered into a multi-year arrangement with Pfizer in 1994 to help offset price competition (see note 2) . The Company expects to continue pursuing additional such arrangements in 1995 .  
Selling, general and administrative expenses for  1994 increased $25 .9 million or 33.1 % over 1993, and 1993 expenses were 
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$33.1 million or 73. 7% greater than in 1992. These increases were attributable to staffing and related costs associated with new con­tracts, added investment in claims processing capability, and con­tinued growth in overhead costs to support growth within the Company's product lines. As a percentage of revenues, selling, gen­eral and administrative expenses decreased to 10.6% for 1994, compared to 11.3% in 1993 and 12.3% in 1992. These decreases were primarily due to greater operating efficiencies from a larger revenue base. During the second half of 1994, selling, general and Years administrative expenses were _ 11.3% _of rev�nues. T�is increase was .Discor due to the effect of CCN which carnes a higher rauo. On an �urin. annual basis, the Company expects these expenses as a percentage of revenues may slightly increase in 1995 due to a full year with CCN results. 
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epreciation and amortization expense, which consists of the depreciation of property and equipment and the amortization of intangible assets arising from acquisitions and purchased and inter­nally developed software, was $19. 7 million for 1994 as compared 
to $13 .9 million in 1993 and $8 .1 million in 1992. The higher level of depreciation and amortization in each year was attributable 
to increased investment in fixed assets to support growth in the Company's business, goodwill amortization resulting from acquisi­tions and increased amortization of capitalized computer software. The Company expects future depreciation and amortization will increase over 1994 levels as a result of $36.9 million in capital additions in 1994 and $30.8 million in goodwill recorded in 1994. 
In 1994, the Company incurred merger-related expense of $6.0 million in connection with its mergers with PrescDrug and RxNet. In 1993, the Company incurred $38 .4 million in merger­related expense associated with its merger with Preferred Health Care Ltd. (see notes 2 and 3) .  
Earnings from continuing operations (excluding merger-related expense) before income taxes in 1994 of $88 .6  million increased by $32 .5  million or 57.9% over 1993 and by $28.7 million or 1 04 .9% over 1992. Earnings improved in each year as a result of revenue growth from new and existing accounts, acquisitions, and ·n 1994 from the Company's arrangement with Pfizer (see note 2) . 
In each year, the provision for income taxes includes, among other things, the utilization of net operating loss carryforwards, the tax benefit associated with certain stock option transactions and an estimate for state income taxes. In 1994 and 1992 the provision for income taxes was also partially the result of goodwill reductions arising from the utilization of certain acquired net operating loss carryforwards. The tax rate was 40%, 60% and 29% for the years ended December 31, 1994, 1993 and 1992, respectively. The increase in the effective rate from 1992 to 1993 is due to a reduc­tion in the benefit of the valuation allowance for deferred taxes and the result of certain nondeductible merger-related expenses recog­nized in 1993. The decrease in the effective rate from 1993 to 1 994 is primarily the result of the higher level of nondeductible merger-related expenses recognized in 1993. At December 31, 1 994, the Company recorded a deferred tax asset of $8 .6  million to reflect the future tax benefits of loss carryforwards and tempo­rary differences (see note 9) . In 1994, the valuation allowance was increased by $0 .7 million to $5 . 0  million primarily due to addi­tional net operating losses from business combinations that were added to the deferred tax asset account. 
Years Ended December 3 1 ,  1 994, 1 993 and 1 992 -
Discontinued Operations 
uring 1993, the Company recorded a loss from discontinued operations of $511,000. This related to an increase in the provi-
sion for state taxes on the gain from discontinued operations which occurred in 1991. During 1992, the Company recorded interest of $256,000, net of taxes, as provided for in the terms of loans receivable related to the discontinued operations of Hospital Advisory Services (see note 13) . 
Liquidity and Capital Resources 
The Company has funded its operations and capital expenditures primarily from the proceeds of stock issuances and internally generated cash. During 1992, the Company completed two public offerings for an aggregate 5 ,889,480 additional shares of common stock. The net proceeds of these offerings were approximately $160. 8  million. 
As of December 31, 1994, the Company had working capital of $ 162 .3  million and unrestricted cash and marketable securities of $ 136.1 million. 
For 1994, net cash provided by operating activities was $22 .8  million. During 1994, the Company incurred cash expenditures in connection with acquisitions and investments of $40.3  million and capital expenditures for property and equip­ment were approximately $36.9 million. 
The Company's joint venture arrangement with Pfizer (see note 2) may require capital contributions of up to $50 million through 1995 .  In addition, the Company may in the future acquire certain businesses or products complementary to its strategy. In connec­tion with such acquisitions, the Company may use its existing liq­uid resources. The Company believes that existing available cash and marketable securities, together with cash from operations, will be sufficient to meet its liquidity and funding requirements for normal operations, at least through 1995 .  
The Company did not pay dividends in 1994 and does not expect to pay dividends in 1995 .  
Inflation 
Health care costs are rising and are expected to continue to rise at rates higher than the Consumer Price Index. The Company believes that its provider discount and risk sharing arrangements, together with its cost control measures such as utilization review and its pricing practices, help to protect against any adverse effect of inflation on its operations. 
Recently Enacted Pronouncements 







Summary of Financial Data 
Year Ended December 3 1 ,  
(In thousands, except per share data) 
T oral Revenues 
Earnings: 
Earnings From Continuing Operations 
Before Cumulative Effect 
of Change in Accounting Principle 
Earnings Per Share From Continuing Operations 
Before Cumulative Effect of Change in 
Accounting Principle 
T oral Assets 
Long Term Liabilities 
Series B Preferred Srock 
Weighted Average Number Of Common Shares Outstanding 









1 993 1 992 
$689 ,45 5  $ 365 ,643 
$ 6,998 $ 1 9,360 
$ 0. 1 7 $ 0 .53  
$482,423 $365 ,752 
$ 7,596 $ 6, 1 1 8 
40,284 36,047 
None None 
Financial data for 1990 and 1991 have not been restated for the 1994 pooling transactions (see notes 2 and 3) as complete financial information 
for the acquired companies was not available. 
1 99 1  1 990 
$ 1 95 , 592 $ 1 23,680 
$ 1 0,292 $ 2,498 
$ 0.34 $ 0 . 1 0  
$ 1 44,767 $ 64, 1 86 
$ 2,960 $ 4,520 
$ 5 ,000 









Consolidated Statements of Operations 
ii 
For the years ended December 3 1 ,  
1 990 
I 
(In thousands, except per share amounts) 1994 1 993 1 992 
--
3,680 Revenues -- Prescription drugs $654,405 $439,842 $225,46 1 
Mental health 198,599 1 6 1 ,643 1 1 4,223 
Insurance services 67,268 35,895 1 ,409 
2,498 I 
Information services 40,721 36,878 1 2,7 1 1 
-- Other 9,710 7,4 13  6, 1 28 
Investment income 5,700 7,784 5,7 1 1 
0. 10  Total revenues 976,403 689,455 365,643 --
i , 186 Expenses 
i ,520 Costs of services 763,631 540,728 284,560 
i ,000 Selling, general and administrative 104,034 78, 140 44,99 1 
i ,345 Depreciation and amortization 15,943 1 1 ,274 6,872 
\Jone Amortization of goodwill 3,708 2,625 1 ,252 
Interest expense 528 603 595 
Merger-related expense 5,986 38,409 
Total expenses 893,830 67 1 ,779 338,270 
Earnings from continuing operations before income taxes 82,573 1 7,676 27,373 
Provision for income taxes 32,952 1 0,678 8,0 13  
Earnings from continuing operations 49,621 6,998 1 9,360 
Discontinued operations, net of taxes - (5 1 1 ) 256 
Net earnings $ 49,621 $ 6,487 $ 1 9,6 16  
Earnings per share: 
Earnings from continuing operations $ 1.19 $ 0. 1 7  $ 0.53 
Discontinued operations - (0.0 1 ) 0.0 1 
Net earnings per share $ 1.19 $ 0. 1 6  $ 0.54 
The accompanying notes are an integral part of the consolidated financial statements. 
Consolidated Balance Sheets � , '
Cons 
December J 1 ,  
(In thousands) 1994 1993 (In the 
Assets Liab 
Cun Current assets: 
Cash and cash equivalents $ 8 1 ,586 $ 61,693 Restricted cash 992 1,348 
Short-term investments 30,688 55 ,048 
Accounts receivable (net of allowance for doubtful accounts 
of $7,877 and $2,298 in 1994 and 1993, respectively) 162,802 103,103 
Deposits in escrow 378 5 ,305 
Prepaid expenses and other current assets 18,401 17,335 To, 
Deferred taxes 6,860 10,642 




Land 1 ,086 955  Cc 
Buildings and improvements 9,228 3,164 St, 
Furniture and fixtures 15 ,338 12,013 Q}]) l.(t Equipment and software 85,328 64,546 
Leasehold improvements 7,328 5 , 5 59 
Construction in progress - 2,715 
1 18,308 88,952 
Less accumulated depreciation and amortization 35,801 25 ,063 
82,507 63,889 
Long-term investments 23,842 63 ,902 I T 
I Goodwill, net 106,268 79,897 
Other assets 22,791 20,261 
152,901 164,060 
Total assets $537, 1 15 $482,423 

























Consolidated Balance Sheets 
(In thousands, except par value) 
Liabilities and Stockholders' Equity 
Current liabilities : 
Payable to providers 
Accounts payable and accrued expenses 
Merger-related expense 
Income taxes payable 
Accrued compensation 
Current portion of capital lease obligations 
Deferred revenue 
Total current liabilities 
Capital lease obligations, less current portion 
Other liabilities 
Total l iabilities 
Commitments and contingencies 
Stockholders' equity: 
Preferred stock-$ .01 par value, authorized 
1,000 shares, none issued 
Common stock-without par value, 
authorized 100,000 shares, issued and outstanding 
40,459 and 39,332 shares for 1994 and 1993, respectively 
Retained earnings 
Unrealized loss on securities available-for-sale, net of tax 
Total stockholders' equity 
Total liabilities and stockholders' equity 







































Consolidated Statements of Changes in Stockholders' Equity 111 . t
cons1 
(In thousands) I (In tho 
I Casli Common Stock Retained 
For the years ended December 3 1 ,  Shares Amount Earnings Total 
Balance at December 3 1 ,  1 99 1  3 1 ,455 $ 93,953 $1 3,796 $107,749 
Issuance of common stock 5,889 1 60,763 1 60,763 
Exercise of common stock options and warrants 1 ,23 1 5,339 - 5,339 
Tax benefits related to common stock option exercises 
and restricted stock activity - 6,948 - 6,948 
Amortization of deferred compensation 325 325 
Issuance of restricted stock 1 2  
Sale of stock to officers 1 6  236 236 
Loans related to officers' stock - (236) - (236) 
Net earnings 1 9,6 16  19,6 16  
Nore receivable from officer - - - (7,950) 
---
Balance at December 3 1  , 1 992 38,603 267,328 33,4 12 292,790 
Exercise of common stock options 7 14  6, 1 35 - 6, 1 35 
Tax benefits related to common stock option exercises 
3,55 1 ©TI �(t and restricted stock activity 3,55 1 
Amortization of deferred compensation - 604 - 604 
Issuance of restricted stock 15  
Net earnings - 6,487 6,487 




Balance at December 3 1  , 1 993 39,332 277,6 1 8  39,899 3 17,5 1 7  
Exercise of common stock options 1 , 1 27 1 4, 12 1  - 1 4, 1 2 1  C 
Tax benefits related to common stock option exercises 
and restricted stock activity 1 0,490 - 10,490 
Amortization of deferred compensation - 1 6 1  1 6 1  
Unrealized loss on securities available-for-sale, net of tax - (292) 
Net earnings - 49,62 1 49,62 1 
Balance at December 3 1 ,  1 994 40,459 $302,390 $89,520 $39 1 ,6 18  
---
The accompanying notes are an integral part of the consolidated financial statements. 
'Consolidated Statements of Cash Flows 
(In thousands) 
Cash flows from operating activities 
Net earnings al Adjustments to reconcile net earnings 49 to net cash provided by (used in) operating activities: 
63 Depreciation and amortization Deferred compensation expense 39 Provision for doubtful accounts 
Deferred taxes 
48 I 
Tax effect on goodwill of acquired loss carryforward utilization 
2.5 Tax effect of certain stock option and restricted stock transactions Amortization of goodwill 
Amortization of deferred revenue 
36 Amortization of investment premiums Other non-cash items 36) Change in assets and liabilities: l 6  (Increase) decrease in assets: 
50) Restricted cash Accounts receivable )0 Other current and non-current assets 15 Deposits in escrow 
Increase (decrease) in liabilities: 
; 1 u 1 �• 
Accounts payable and accrued expenses 












Net cash provided by operating activities 
Cash flows from investing activities 
Capital expenditures 
Acquisitions and investments, net of cash acquired 
Advances under loan agreement 
Repayments of advances under loan agreement 
Purchases of investment securities 
Proceeds from maturities and sales of investment securities 
Net cash used in investing activities 
Cash flows from financing activities 
Net proceeds from issuance of common stock 
Proceeds from exercise of common stock options and warrants 
and issuance of restricted stock 
Payments of long-term debt and capital lease obligations 
Loan to officer 
Repayment of loan to officer 
Net cash erovided b}" financing activities 
. Net increase in cash and cash equivalents ' Cash and cash equivalents at beginning of year 
Cash and cash equivalents at end of year 
The accompanying notes are an integral part of the consolidated financial statements. 
For the yeors ended December 3 1 ,  
1994 1993 
$ 49,621 $ 6,487 
1 5,943 1 1,274 
161  604 
6,341 1,267 
5 , 153 (6,026) 
416 
10,490 3,55 1 
3,708 2,625 
(4,871)  (3,723) 
826 2,255 
- 26 1 
356 (2 1) 
(57,766) (40,500) 
(3,8 17) ( 14,431) 
4,927 (3,467) 
(3, 147) 10,756 
( 10,374) 28,4 16 
9,920 31,344 
(6,240) 8 ,7 18 
2,606 4,6 13 
( 1 ,459) (79) 
(26,827) 37,437 
22,794 43,924 
(36,948) (35 ,765) 
{40,334) (25 ,954) 
{1 ,039) (5 ,778) 
- 4, 182 
{86,857) ( 152,736) 
1 5 1 ,044 176,846 
( 14, 134) (39,205) 
- -
14, 12 1  6, 135 
(2,888) ( 1,9 17) 
- -
- 7,950 
1 1 ,233 12, 168 
19,893 16,887 
61 ,693 44,806 
$ 8 1 ,586 $ 6 1,693 
1992 
- - - -
$ 19,6 16 
6,872 325 1,058 ( 1,787) 64 1 6,948 1,252 (2,7 16) 662 2 19 
384 ( 13,0 18) (4,609) (46) 
7,804 
14,598 (5 ,666) 3,390 4 1  
16,352 
35 ,968 
( 15 ,296) (39,077) ( 1,647) 
(2 18,2 18) 95 ,426 
( 178 ,8 12) 
160,763 
5 ,339 ( 1,266) (7,950) 
-- --156,886 14,042 30,764 
$ 44,806 
"' "' 
Notes To Consolidated Financial Statements 
1 Summary of Significant Accounting Policies 
Principles of Consolidation The consolidated financial statements include the accounts of the Company and all its subsidiaries . All significant inter-company balances and transactions have been eliminated. 
Cash and Cash Equivalents For purposes of reporting cash flows, investments with original maturities of three months or less are considered to be cash equivalents. 
Restricted Cash Restricted cash consists of amounts on deposit in compliance with state regulatory requirements and building and equipment lease agreements. 
Deposits in Escrow Pursuant to contracts with certain program sponsors, deposits in escrow are established in which the funds can be used, under certain conditions, to pay claims as specified in the agreements. 
Inventories Inventories consist of prescription drugs and are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. Inventories of $9,011,000 and $6 ,859,000 are included in prepaid expenses and other current assets at December 31, 1994 and 1993, respectively. 
Investments Effective January 1, 1994, the Company adopted Statement of Financial Accounting Standards No. 115 ("SFAS 115") . Under SFAS 115 ,  the Company has classified its investments in debt securities as "available-for-sale" securities and carries such securities at market value. Accordingly, the net unrealized gain or loss, net of tax, is included as a separate component of stockholders' equity. Prior to 1994, all investments were classified as held-to-maturiry. Under this classification, short-term investments were carried at the lower of cost or market and long-term investments at amor­tized cost. At December 31, 1993, long-term investments were those investment securities which the Company had the intent and the abiliry to hold to maturiry. Premiums are amortized on a straight-line basis until maturiry. In determining the gain or loss on sales of investments, cost is based on specific identification of the asset sold. 
Fixed Assets Fixed assets are recorded at cost. The Company uses straight-line and accelerated methods of depreciation over the estimated useful lives of the assets , which range from three to twenry-five years. Assets acquired under capital lease agreements are recorded at the lesser of the present value of the minimum lease payments or the fair value of the properry. 
These assets are amortized on a straight-line basis over periods consistent with the Company's depreciation policy for similar pur­chased assets or over the lease term, whichever is less . 
Expenditures for maintenance and repairs are charged to income as incurred and renewals and improvements are capitalized. Upon sale or retirement of fixed assets, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. 
Included in equipment at December 31, 1994 and 1993 are capital­ized computer software costs, related to purchased software and software developed internally for sale as part of its product lines, of $23,791,000 and $21,301,000, respectively. The Company capital­izes costs of software to be sold once technological feasibility has been established. Accumulated amortization on computer software was $6,221,000 and $5 ,021,000 at December 31, 1994 and 1993, respectively, and is included in accumulated depreciation and amor­tization. The Company uses the straight-line amortization method over estimated useful lives which range from three to five years. 
Goodwill Goodwill related to acquisitions represents the excess of cost over fair value of net tangible and separately identifiable intangible assets acquired, and is amortized on a straight-line basis over 15 to 40 years. Accumulated amortization was $9,712,000 and $5 ,733,000 at December 31, 1994 and 1993, respectively. The Company reviews its amortization policy and carrying value of goodwill on an ongoing basis. This review includes an analysis of whether carrying values and amortization periods are appropriate based upon product life cycle, Company performance compared to expectations and industry practice. 
Payables to Providers Payables to providers are recorded as services are rendered. The costs of claims for services rendered but not yet reported are estimated based on historical data, current enrollment statistics, patient census data and other information. Such estimates and the resulting accrued liabilities are periodically reviewed and updated. Any adjustments resulting therefrom are reflected in earnings currently. 
Deferred Rent The Company has received rent abatements for limited periods in connection with leases for certain office space. Costs associated with these leases, recorded on a straight-line basis over the full lease term, resulted in a deferred rent liabiliry of $1,324,000 and $799,000 at December 31, 1994 and 1993, respectively. 
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Revenue is recognized at the time related services are performed. 
Revenue from sales of prescription drugs is recognized at the time 
of shipment. Deferred revenue represents amounts advanced to the 
Company on contracts for which performance is expected to be 
completed in future periods. 
Revenues recognized from billings to a major customer represented 
9.3%, 8.0% and 13.2% of consolidated total revenues for the years 
ended December 31, 1994, 1993 and 1992, respectively. 
Licensure Costs 
Costs directly incurred to obtain licenses to do business in new 
market areas are capitalized and amortized on a straight-line basis 
over three years. 
Income Taxes 
The Company files a consolidated federal income tax return which 
includes all of its subsidiaries. The Company's income tax liability 
has been determined under the provisions of Statement of Financial 
Accounting Standards No. 109, Accounting far Income Taxes 
� - ("SFAS 109"), requiring an asset and liability approach for finan­, lcial accounting and reporting for income taxes. The liability is 
based on the current and deferred tax consequences of all events 
recognized in the consolidated financial statements as of the date 
of the consolidated balance sheet. Deferred taxes are provided for 
temporary differences which will result in taxable or deductible 
amounts in future years, primarily attributable to a different basis 
in certain assets for financial and tax reporting purposes, including 
recognition of deferred tax assets net of a related valuation allowance. 
Common Stock Split 
On August 6, 1992, the Board of Directors authorized a stock split 
of 3-for-2 effected as a stock dividend on outstanding shares of 
common stock. All shares and per share amounts have been 
retroactively restated in the consolidated financial statements to 
give effect to the split. 
Net Earnings Per Share 
Net earnings per share are based on the weighted average number 
of common shares and common share equivalents (if dilutive) 
resulting from options outstanding during the periods, after 
giving retroactive effect to the common stock split. The weighted 
average number of common shares and common share equivalents 
outstanding is approximately 4 1,585,000, 40,284,000 and 
36,047,000 for the years ended December 31, 1994, 1993 
and 1992, respectively. There is not a significant difference 
between primary and fully diluted earnings per share. 
Reclassifications 
Certain amounts from the 1992 consolidated financial statements 
are reclassified to conform with the 1993 and 1994 presentation. 
2 Mergers and Acquisitions, Joint Venture, Investments and 
Advances 
On August 29, 1994, the Company completed its merger with 
PrescDrug. The Company issued 937,178 shares of its common 
stock in exchange for all of die outstanding common stock of 
PrescDrug at an exchange ratio of 1: 1. 
On August 31, 1994, the Company acquired by merger all of the 
outstanding common stock of RxNet by issuing 256,136 shares 
of its common stock for all of the outstanding common stock of 
RxN et at an exchange ratio of 1: 1. 
Both of these transactions have been accounted for as poolings of 
interests and financial statements for all periods prior to these 
combinations have been restated to reflect the combined operations. 
Included in the consolidated results of operations for the year ended 
December 31, 1994 are the following unaudited results of the 
previously separate companies for the period January 1, 1994 to 
June 30, 1994: 
(In thousa nds) C omeanr P rescD rug RxN et C ons olidat ed T otal revenu es $4 1 4 ,857 $25 , 1 63 $ 1 4,60 1 $454,62 1 N et ea rnings $ 23,749 $ (87) $ (678) $ 22,984 
The following are reconciliations of revenues and net earnings pre­
viously reported by the Company for the years ended December 31, 
1993 and 1992, with the combined amounts currently presented in 
the financial statements for those years: 
(In thousands) Year ended December 3 1 ,  1 993 C omeanr P rescD rug RxN et C ons olidat ed T otal revenu es $6 1 4, 1 5 1  $48 , 1 86 $27, 1 1 8  $689,455 N et ea rnings $ 8, 1 03 $ 377 $ ( 1 ,993) $ 6,487 
(In thousa nds) Yea r ended December 3 1 ,  1 992 C omeanr P rescD rug RxN et C ons olidat ed T otal rev enu es $3 1 7,840 $46,9 1 8  $885 $365 ,643 
N et ea rnings $ 20,546 $ (958) $ 28 $ 1 9,6 1 6  
"' " 
Notes To Consolidated Financial Statements 
On December 14, 1993, the Company completed its merger 
with Preferred Health Care Ltd. ("Preferred"). The Company's 
American Psych-Management, Inc. ("APM") subsidiary and 
Preferred's mental health and substance abuse division have each 
become wholly-owned subsidiaries of the Company's Value 
Behavioral Health, Inc. subsidiary, headquartered in Falls Church, 
Virginia. Workers' compensation and related services are provided 
by Preferred Works, Inc. (formerly named Adjustco, Inc., a sub­
sidiary of Preferred), headquartered in Wilton, Connecticut. 
The transaction was accounted for as a pooling-of-interests in 
which each share of Preferred common stock was exchanged for 
.88 shares of the Company's common stock. The Company issued 
10,958,841 shares of its common stock to effect the merger. 
Financial statements for all periods prior to the combination have 
been restated to reflect the combined operations. 
All other acquisitions by the Company, since its inception, were 
accounted for as purchases. The purchase prices assigned to the 
net assets acquired were based on the fair value of such assets and 
liabilities at the respective acquisition dates. 
On November 19, 1991, the Company completed its acquisition 
of Cost Containment Corporation of America ("CCC"), a pre­
scription drug management company. At closing, the minimum 
purchase price (as defined in the agreement and plan of merger) of 
$5.4 million was paid by the issuance of 406,962 shares of com­
mon stock of which 101,741 shares are being held in escrow sub­
ject to the satisfaction of certain conditions. Up to 1,452,054 
additional shares could be earned over a four-year period. The 
excess cost over net liabilities acquired of $14.3 million was 
recorded as goodwill and is being amortized over 25 years. Any 
additional shares issued will result in an increase in goodwill. 
On October 30, 1992, the Company completed its acquisition 
of Stokeld Health Services Corporation ("Stokeld"), a Davenport, 
Iowa based mail order pharmacy provider, which has been renamed 
VaiueRx of lowa, Inc. In the transaction, the Company acquired 
all of the outstanding common stock of Stokeld for $9.9 million 
and advanced $6.3 million to Stokeld to retire certain of its 
liabilities. Goodwill of $14. l million was recorded and is being 
amortized over 40 years. 
On December 1, 1992, Value Health completed its acquisition of 
Lewin-ICF, Inc. ("Lewin"), a national health policy and manage­
ment consulting firm based in the Washington, DC area, from 
ICF International, Inc. Lewin provides health policy consulting, 
contract research and management consulting services. In connec­
tion with the acquisition, the Company acquired all of the out­
standing common stock of Lewin for $11.0 million in cash. In 
addition, the Company paid certain senior managers of Lewin 
$ 1.0 million in cash at closing, and will pay up to $3.0 million 
depending upon the financial performance of Lewin during 1993, 
1994, and 1995, in exchange for their rights in certain intellectual 
property. The Company also paid approximately $0.6 million to 
certain managers in connection with the termination of certain 
benefits. Goodwill of $8.8 million was recorded and is being 
amortized over 15 years. Lewin has been renamed Lewin-VHI, Inc. 
On December 31, 1992, the Company purchased all of the out­
standing stock of Adjustco, Inc., a Delaware corporation which 
has been renamed Preferred Works, Inc. ("PWI") .  PWI provides 
claims administration, adjusting, processing, and related services 
to insurance companies and self-insured businesses throughout 
the United States. The purchase price was $7.0 million in cash. 
Goodwill of $7.9 million was recorded and is being amortized 
over 35 years. 
On December 31, 1992, the Company also acquired all of 
the outstanding stock of Diversified Medical Resources 
Corporation, which has been renamed Value Medical Resources 
Corporation ("VMRC"). VMRC provides independent medical 
examinations and other services to insurance companies and law 
firms for workers' compensation, personal injury and product lia­
bility injury claims. VMRC_ is headquartered in Minneapolis, 
Minnesota. The purchase price was $2.9 million in cash and 
contingent consideration of $2.0 million payable in 1994 and 
$1.0 million payable in 1995, based upon achieving certain rev­
enue and profit goals. No 1994 payment was made as the revenue 
and profit goals were not met. Such contingent consideration 
will be recorded as additional goodwill if paid. Goodwill of 
$2.7 million was recorded and is being amortized over 35 years. 
On January 13, 1993, the Company completed its acquisition of 
Wellington Life Insurance Company, an insurer based in Arizona 
with insurance and reinsurance licenses in 32 states, for $6.3 mil­
lion in cash. The purchase price was equal to the fair value of the 
net assets acquired. 
On July 20, 1993, the Company acquired all of the outstanding 
shares of Square Lake Corporation ("SLC") for $3.6 million in 
cash and contingent consideration of up to $8.4 million if certain 
revenue goals are met. Goodwill of $4.5 million was recorded 
and is being amortized over 35 years. SLC, based in Michigan, 
specializes in managed care programs for HMOs and PPOs in the 
areas of mental health and substance abuse treatment. 
On July 29, 1993, the Company's Value Health Sciences, 
Inc. ("VHS") subsidiary purchased the assets and assumed 



















$1.6 million in cash and contingent consideration of up to 
$1.0 million during 1994 and 1995 based upon achieving certain 
revenue levels. In September, 1994, $0.5 million of contingent 
consideration was paid. Additional contingent consideration will 
be recorded as goodwill if paid. Goodwill of $1. 8 million has been 
recorded and is being amortized over 15 years. The Raleigh Group 
offers data analysis and consulting services to health care insurers 
and providers. 
On August 1, 1993, APM completed its acquisition of the Center 
for Human Resources, Inc. ("CHR") for $1.1 million in cash. Of 
this amount, $0.2 million was placed in escrow and was paid in 
September, 1994 upon the achievement of certain seller warranties 
and representations. In addition, APM may pay contingent con­
sideration of up to $0.8 million, depending upon the achievement 
of certain revenue levels between June, 1993 and February, 1995. 
Goodwill of $1.1 million was recorded and is being amortized 
over 25 years. CHR is an employee assistance company based in 
Fairfax, Virginia. 
On October 1, 1993, the Company's ValueRx Pharmacy Program, 
Inc. ("VRx") subsidiary purchased the assets of the Associated 
Prescription Services division of United HealthCare, Inc. ("APS") 
for $7. 7 million in cash. Of this amount, $1.1 million was held in 
escrow and was released in March, 1994 upon the fulfillment of 
contractual warranties, representations and consents. VRx may pay 
additional contingent consideration of up to $0.4 million on or 
before June 30, 1995 if certain revenue objectives are mer. This 
contingent consideration will be recorded as additional goodwill if 
paid. Goodwill of $7.5 million was recorded and is being amor­
tized over 25 years. APS provides prescription drug management 
services and is based in Balrimore, Maryland. 
VRx completed its acquisition of the remaining 92% of Complete 
Pharmacy Network ("CPN") on November 3, 1993, for $7.5 million 
in cash. Prior to char date, the Company held an 8% interest in 
CPN which was included in other assets and carried at cost. Upon 
completion of the acquisition, goodwill of $9.9 million was 
recorded and is being amortized over 25 years. CPN is a retail 
pharmacy preferred provider organization based in Medina, Ohio. 
On June 21, 1994, the Company completed its acquisition of 
CCN. The purchase price was $40.0 million in cash and contin­
gent consideration of up to an additional $80.0 million. The 
�- contingent consideration is payable in cash and is based upon 
CCN' s earnings during a twelve month calculation period, which 
period will end not lacer than December 31, 1996. Goodwill of 
$23.4 million was recorded and is being amortized over 35 years. 
Any contingent payments will be recorded as additional goodwill. 
The following unaudited pro forma consolidated results of 
operations assume char the CCN acquisition occurred on 
January 1, 1993. 
(Unaudited) In thousands, 
except per share amounts 
Year Ended December 3 1 ,  





50, 1 22 
1 .2 1  
1 993 
$738,93 1 
$ 24,7 1 5 
$ 1 0 ,678 
$ 0.27 
The pro forma resulrs of operations do not purport to be indica­
tive of the results which would actually have been obtained had the 
acquisition occurred on the dares indicated or which may be 
obtained in the future. 
On May l ,  1994, the Company and Pfizer Inc ("Pfizer") entered 
into a joint venture partnership to develop specialry disease 
management programs. The partnership is owned equally by 
VHI Venturer, Inc., a wholly-owned subsidiary of the Company 
and Pfizer Healch Sciences, Inc., a wholly-owned subsidiary of 
Pfizer. Each partner has committed to contribute up to $50 mil­
lion of capital, subject to approval of specific business plans. 
Further, the Company entered into a mulri-year contract with 
Pfizer to develop value-added programs designed to improve 
physician and patient use of Pfizer prescription and medical device 
products. In addition, several Pfizer drug products will receive 
assured positions on Value Health's prescription drug formularies 
in return for rebate arrangements. 
On December 9, 1993, the Company purchased for $3.0 million 
a 5.4% interest in HSI, a developer and manager of physician 
group practices based in Reston, Virginia. The investment in 
HSI is included in ocher assets at December 31, 1994 and 1993. 
On December 28, 1994, the Company sold a non-refundable 
option on its 5.4% interest to Warburg Pincus Capital Company, 
L.P. ("Warburg") for $4.0 million. The option is exercisable 
through March 15, 1995. 
On July 29, 1993, the Company, in connection with an invest­
ment by Warburg to finance the development of Value Health 
Management, Inc. ("VHM"), entered into a loan agreement with 
VHM ("the Agreement"). Under the Agreement, the Company 
may provide VHM up to $3.0 million in loans. In addition, the 
Company obtained options to purchase from VHM stockholders, 
all of the outstanding common and preferred stock of VHM. 
The exercise price for the common stock will be calculated based 
upon VHM's performance during specified time periods through 
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to January 1, 1996. As of December 31, 1994, loans to VHM, 
including relocation amounts, were $2,975,000 and are included 
in other assets. The loans, which mature on December 2, 1996, 
bear interest at one percent above the prime rate, and are carried at 
cost. In January, 1995, VHM repaid $975,000 of loans. 
3 Merger-Related Expense 
During the third quarter of 1994, the Company recorded a charge 
of $6.0 million in connection with its mergers with PrescDrug and 
RxNet. Of this amount, approximately $2.8 million was incurred 
for transaction costs and $3.2 million was related to costs associat­
ed with the combining of operations and the related restructuring 
activities, such as reduction of head count and elimination of 
duplicate facilities and excess capaciry. 
During the fourth quarter of 1993, the Company recorded a 
charge of $38.4 million in connection with its merger with 
Preferred. Of this amount, approximately $9.3 million was 
incurred for transaction costs and $29 . 1  million was related to 
costs associated with the combining of operations and the related 
restructuring activities, such as the reduction of head count and 
elimination of duplicate facilities and excess capaciry. 
The following table is a reconciliation of the merger-related 
expense for the years ended December 31, 1994 and 1993. 
(In thousands) 
Balance at 
December 3 1 ,  1 992 
Expenses recorded 
Payments and wrireoffs 
Balance at 
December 3 1 ,  1 993 
Expenses recorded 
Payments and writeoffs 
Balance at 
December 3 1 ,  1 994 












Asset Head Count 
Writeoffs and Caeaci� 
$ - $ -
9,689 1 9 ,452 - ( 1 ,675) 
9,689 1 7,777 
1 , 1 93 1 , 993 
(9,689) ( 1 2,966) 









Future minimum lease payments under noncancelable capital 
leases having terms in excess of one year are as follows: 
Years ended December 3 1 :  





Total future minimum lease payments 
Less amount representing interest 
Present value of minimum lease payments 
Less current portion 
Capital lease obligations, less current portion 
$2,575 ,000 







(2, 1 47,000) 
$3 ,442,000 
Included in fixed assets are the following assets under capital leases: 
Furniture and fixtures 
Equipment 









$2, 8 1 7,000 
6,766,000 
9 ,583 ,000 
3 ,542,000 
$6,04 1 ,000 
The Company has cancelable and noncancelable operating lease 
agreements for equipment and office space which include renewal 
options. Total rental expense was $ 16, 153,000, $ 15,535,000 and 
$6,727,000, in 1994, 1993 and 1992, respectively. The Company's 
minimum future lease payments under noncancelable operating 
leases are as follows: 







5 Capital Stock 
$ 1 6,873,000 
1 4,77 1 ,000 




$ 1 05 ,236,000 
The Company has one class of common stock outstanding. At 
December 31, 1994, there were 40,459,000 shares of common 
stock outstanding. In February, 1991, the Company amended 
its charter to authorize 1,000,000 shares of undesignated preferred 
stock, $.01 par value per share. No undesignated preferred shares 
are issued or outstanding. 
In June, 1993, the Company amended its Certificate of 
Incorporation to increase the number of authorized shares of 
the Company's common stock without par value from 
















































» I ((( I In connection with a Shareholder Rights Plan adopted in February, 1994, the Company granted to holders of record of the Company's common stock on March 7, 1994, a preferred stock purchase right for each share of common stock held. The rights entitle stockholders, in certain circumstances, to purchase 111000th of a share of the Company's Series A Junior Participating Preferred Stock at an exercise price of $120. 
6 Stock Option Plans 
In 1987, the Company adopted the 1987 Stock Plan (the "1987 Plan") which provided that incentive stock options could be granted to officers and key employees and certain non-qualified options could be granted to purchase up to an aggregate of 1,358,577 shares of common stock. Options are exercisable in installments as deter­mined by the Board of Directors of the Company. Incentive stock options that are granted have terms not exceeding 10 years and exer­cise prices not less than the fair market value at the date of grant. 
In February, 1991, the Company adopted the 1991 Srock Plan (the "1991 Plan") .  The 1991 Plan provides that options to pur-
((fchase up to 1,912,500 shares of Company common stock may be granted to officers and key employees. Under the 1991 Plan, the Company may grant incentive stock options, non-qualified stock options, restricted stock, stock appreciation rights and perfor­mance units. Options are exercisable in installments as determined by the Company. Incentive stock options must have a term not exceeding 10 years and an exercise price not less than the fair mar­ket value of the Company common stock on the date of grant. 
On June 14, 1990, the Company amended and restated the Srock Incentive Plan (the "Preferred Plan") . The Preferred Plan provides that up to 1,751,000 shares of common stock may be subject to stock options or awards of restricted stock, and the number of shares subject to the Preferred Plan shall be increased annually by an amount equal to 3% of the shares outstanding at the end of the preceding year, unless the Board of Directors authorizes a lesser amount. During 1993, an additional 313,619 shares of common stock were authorized for issuance under the Preferred Plan. Options and awards are exercisable in installments as determined by the Company. In addition, the Company has granted options to certain consultants that are not included in the Preferred Plan. 
On May 4, 1994, the Company amended and restated the 1991 
f Plan to provide that the shares issuable under the 1991 Plan be increased each year by a number of shares equal to two percent of the Company's common stock outstanding at the end of the immediately preceding year plus such number of shares as were available for grant in any preceding year and were not otherwise 
granted. During 1994, an additional 762,780 shares of common stock were authorized for issuance under the 1991 Plan. 
On the date of the merger with Preferred, the Company replaced all options outstanding under the Preferred Plan with options to purchase shares of the Company's common stock based on the exchange ratio of . 88  to 1.  
Common stock option transactions under the 1987 Plan, the 1991 Plan, and the Preferred Plan, as adjusted for the stock split, follow: 
Common Options Outstanding 
Shares Average 
Available Common Option 
For Grant Shares Price 
Balance, December 3 1 ,  1 9 9 1  2 ,864,866 2,002,950 $ . 0 1 -22. 59 
Change in shares reserved 300,502 
Options: 
Granted ( 1 ,82 1 , 1 00) 1 ,82 1 , 1 00 1 0 . 5 1 -36. 1 3  
Exercised - (442,954) . 0 1 -2 1 .83 
Forfeited 2 1 4,406 (2 1 4,406) 6.07-3 1 .00 
Balance, December 3 1 ,  1 992 1 , 5 58 ,674 3 , 1 66,690 .0 1 -36. 1 3  
Change i n  shares reserved 730,803 
Options: 
Granted ( 1 ,602,740) 1 ,602,740 1 5 .63-39.00 
Exercised - (673,95 I ) . 0 1 -32.00 
Forfeited 1 70, 1 59 ( 1 70, 1 59) 5 .94-36. 1 3  
Balance, December 3 1 ,  1 993 856,896 3,925 ,320 . 0 1 -39.00 
Change in shares reserved 857,760 
Options: 
Granted ( 1 ,028,900) 1 ,028,900 30 .50-48.00 
Exercised - ( 1 ,07 1 ,702) . 0 1 -39 .00 
Forfeited 5 1 , 1 57 (5 1 , 1 57) 5 .94-42.25 
Balance, December 3 1 ,  1 994 736,9 1 3  3,83 1 ,36 1 $ . 0 1 -48.00 
Options exercisable to purchase shares of common stock under the above plans at December 31, 1994, 1993 and 1992 were 1,664,349, 1 ,388 ,693 and 1,390,745 respectively. 
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On June 29, 1990, the Company issued certain other non­
qualified options to purchase 480,000 shares of its common stock 
at $.0073 per share. These options were issued outside the 1987 
Plan under separate agreements. During 1994, 1993 and 1992, 
approximately 9,926, 2,500, and 16,000 of these options were 
exercised, respectively. Of these options, 8,303 were exercisable at 
December 3 1, 1994. 
In February, 1991, the Company adopted the 199 1 Non­
Employee Director Stock Option Plan (the "Directors' Plan"). 
The Directors' Plan provides that options to purchase up to 
1 12,500 shares of the Company's common stock may be granted 
to certain non-employee directors of the Company. The exercise 
price per share of options granted under the Directors' Plan will be 
equal to the fair market value of the Company's common stock at 
the date of grant. Options granted under the Directors' Plan expire 
five years from the date of grant. One-half of the shares covered by 
the options become exercisable upon the date of grant and the 
remaining one-half of such shares become exercisable on the first 
anniversary of the date of grant. On May 4, 1994, the Company 
amended and restated the Directors' Plan to provide for: (i) the 
increase in the number of shares of common stock subject to the 
Directors' Plan from 112,500 to 250,000; (ii) the automatic annu­
al grant of vested options to acquire up to 2,500 shares of the 
Company's common stock to continuing eligible directors begin­
ning upon the second anniversary of initial election to the Board; 
(iii) the automatic grant of vested options to acquire an additional 
500 shares to such continuing directors who serve as Chairmen of 
the Company's Audit Committee or Compensation Committee; 
and (iv) the extension of the period of time such options are exer­
cisable from five years to ten years. At December 3 1, 1994, options 
to purchase 67,500 shares of common stock at prices ranging 
from $8.00 to $33.25 per share had been granted. Approximately 
67,240 of these options were exercisable at December 31, 1994. 
In November, 199 1, Preferred's Board of Directors approved the 
199 1 Directors' Stock Option Plan (the " 199 1 Directors' Plan"). 
Under the 199 1 Directors' Plan, certain non-employee directors of 
the Company were each granted options to purchase 4,400 shares 
of the Company's stock. The options under the 199 1 Directors' 
Plan were immediately vested and exercisable at the fair market 
value of the Company's common stock at the date of grant. During 
1993 and 1992, the 1991 Directors' Plan granted options for 13,200 
and 17,600 shares, respectively. No shares were granted in 1994. 
On May 4, 1992, 142,406 options with original grant prices 
between $22.58 and $17.33 were repriced to $15.48, the market 
value at that date. On June 30, 1992, 286,488 options with grant 
prices between $15.48 and $ 14.85 were repriced to $11.36, the 
market value at that date. 
7 Other Employee Benefits 
In February, 199 1, the Company established the 199 1 Employee 
Stock Purchase Plan (the "Purchase Plan"), providing for the 
purchase, by employees of the Company, of up to 750,000 shares 
of common stock. The Purchase Plan commenced May 1, 1991. 
All employees of the Company on May 1, 199 1, and all persons 
who become employees thereafter are eligible to participate in the 
Purchase Plan. Employees who own five percent or more of the 
Company's stock and directors who are not employees of the 
Company may not participate in the Purchase Plan. During 1994, 
1993 and 1992, participating employees purchased 53,945, 
33,830, and 34,344 shares, respectively, of common stock under 
the Purchase Plan at average prices of $30.54, $27.26 and $ 15.81  
per share, respectively. 
The Company adopted a 40 1 (k) Retirement Savings Plan (the 
"Savings Plan") for all employees, which became effective on 
May 1, 199 1. The Company made matching contributions to the 
Savings Plan, subject to certain limitations, equal to 100% of 
each participant's pre-tax contribution of an amount up to 2% of 
such participant's total compensation and 50% of the next 2% 
of such participant's compensation in 1993 and 1994. The 
Company match in 1992 was 50% of each participant's pre-tax 
contribution on an amount up to 4% of such participant's total 
compensation. All employees of the Company on May 1, 199 1, 
and all persons who become employees thereafter and complete at 
least one year of employment with the Company, are eligible to 
participate in the Savings Plan. The Company's matching contri­
bution expense was $929,000, $724,000 and $240,000 in 1994, 
1993 and 1992, respectively. 
The Company also maintains the Preferred Health Care Savings 
and Investment Plan, a qualified defined contribution plan with 
Section 40 l (k) features (the "Preferred Savings Plan"). The 
Preferred Savings Plan covers employees who are at least 2 1  years 
of age and have at least approximately three months of service. 
Participants may elect to have a portion of their pre-tax salary paid 
by the Company to the trustees under the Preferred Savings Plan. 
The Preferred Savings Plan also provides that the Company may 
make contributions, up to certain limits, of a percentage of the 
salary contributions made by the participants. During 1994, 1993 
and 1992, the Company contributed $284,000, $370,000 and 






















The Company also maintains the Community Care Network, Inc. 
40 1 (k) Savings Plan, a qualified defined contribution plan (the 
"CCN Plan"). All employees of CCN on August 1, 1989 and all 
persons who become employees thereafter and complete at least six 
months of employment with CCN are eligible to participate in the 
CCN Plan. CCN made matching contributions to the CCN Plan, 
subject to certain limitations of 100% of each participant's pre-tax 
contribution of an amount up to 5% of compensation. Included 
in 1994 consolidated resulcs of the Company are marching contri­
butions of $356,000 under the CCN Plan. 
8 Supplemental  Disclosures of Cash Flow Information 
1994 
Cash paid du ring the yea r fo r: Inte rest $ 449,000 Income ta xes $13,472,000 Noncash t ransactions: Capita l leases ente red into fo r  equipment $ 73 1 ,000 
((f Income Taxes 
1 993 1 992 
$ 640,000 $ 5 54,000 
$5 ,852,000 $ 1 0,793,000 
$5 ,008,000 $ 3, 428,000 
The provision for income taxes for the years ended December 31, 
1994, 1993 and 1992 consisted of the following: 
1994 1 993 1 992 
Cu rrent ly payab le: Fede ra l  $25,841 ,000 $ 1 4,452,000 $9,049,000 State 4,000,000 2, 1 1 1 ,000 1 , 1 2 1 ,000 Defe rred ta xes: Fede ra l  p rovision (benefit) 2,026,000 (7,343,000) ( 1 ,06 1 ,000) Va luation a llowance 669,000 1 ,458 ,000 ( 1 ,737,000) Goodwi ll reduction fo r  acqui red net ope rating loss ca rryfo rwa rd uti lization 416,000 - 64 1 ,000 
$32,952,000 $ 1 0,678,000 $8 ,0 1 3,000 
Taxes payable for 1994, 1993 and 1992 were reduced by 
$10,490,000, $3,551,000 and $6,948,000, respectively, for the 
tax benefit of disqualified dispositions of common stock and the 
exercise of non-qualified common stock options. 
The tax benefits of carryforwards and temporary differences 
related to the deferred tax asset at December 3 1, 1994 and 1993 
are as follows: 
Ca rryfo rwa rds: Net ope rating loss ca rryfo rwa rds re lated to pu rchase business combinations 
Tempo ra ry diffe rences: Me rge r- re lated e xpense Estimated c laims liabi lities Dep reciation and amo rtization Rese rves and othe r 
G ross defe rred ta x benefit Va luation a llowance 
Net defe rred ta x benefit Less cu rrent po rtion 





( 1 ,500,000) 
6,649,000 





$ 1 ,730,000 
1 993 
$ 4, 549,000 
7,986,000 
2,49 1 ,000 
(2, 1 5 1 ,000) 
2 ,7 1 7,000 
1 1 ,043,000 
1 5 , 592,000 
(4,307,000) 
1 1 ,285 ,000 
1 0,642,000 
$ 643,000 
The valuation allowance was increased in 1994 by $669,000 in 
connection with additional net operating losses from business 
combinations that were added to the deferred tax asset. The valua­
tion allowance of $4,976,000 has been maintained primarily due 
to the uncertainty regarding the riming of net operating loss uti­
lization related to certain business combinations. At December 31, 
1994, the valuation allowance included approximately $900,000 
for net operating loss carryforwards related to purchase business 
combinations. Should deferred tax assets subsequently be recog­
nized for such carryforwards, the reduction of the valuation 
allowance will be offset by a corresponding reduction of goodwill. 
In connection with the acquisition of PWI, the Company elected 
to treat the acquisition as an asset purchase rather than a stock 
purchase for income tax reporting purposes. As a resulc of that 
election, PWI was able to utilize approximately $5, 160,000 of 
net operating losses to offset the resulting tax gain. In addition, 
the election had the effect of increasing the tax basis of goodwill, 
which is now deductible for tax purposes under the provisions of 
the Omnibus Budget Reconciliation Act of 1993. The Company 
has reduced its deferred tax accounts as they relate to the allocation 
of purchase price to account for the utilization of the net operating 
losses. 
The Company's effective tax rate on earnings from continuing 
operations before income taxes and cumulative effect of change in 
accounting principle differs from the federal statutory regular tax 
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( 1 .2) 
















(0 .9)  
(2.3) 




(0 .1 ) 
29.3% 
The Company had the following income tax carryforwards avail­able at December 31, 1994: 
U .S .  fede ral regul ar net ope rating loss c arryfo rw ards acqui red in pu rc hase business combin ations av ail able fo r  offset ag ainst futu re t axable income U .S .  fede ral AMT net ope rating loss c arryfo rw ards acqui red in pu rc hase business combin ations 
1 0 Related Parties 
T ax Repo rting 
Ye ars of Amount E xpi ration 
$6,740,000 2002-7 
$6,471 ,000 2002-7 
On July 2, 1990, a subsidiary of the Company loaned an aggregate principal of $160,000 at 10% to an executive officer. Of that amount, $60,000 was repaid in 1993 and $100,000 was repaid in 1994. The amounts receivable from the executive officer at December 31, 1994 and 1993, including accrued interest, were $0 and $125 ,000, respectively. The amounts receivable are carried at cost which approximates fair value. 
The Co'mpany entered into a five year employment contract with an executive officer as a result of the acquisition of certain sub­sidiaries. The employment contract terminated in 1993. An acqui­sition liability was established at the inception of the employment contract and was amortized through 1992. Acquisition liability amortization was $0, $0, and $80,000 in 1994, 1993 and 1992, respectively. 
In January, 1991, a previously acquired company was sold back to an executive officer. The purchase price was $1, and the Company made a working capital contribution of $20,000. The executive officer guaranteed payment of a pre-existing note from the former subsidiary to the Company of $111,000 by the pledge of 71,467 shares of the Company's common stock. The note bears interest at 5 . 5% and is due November 30, 2006. 
Pursuant to a 1988 agreement, the Company acquired for $230,000 a 27% equity interest in a house purchased by the President of one of its subsidiaries. The Company is entitled to a proportional share of the proceeds when the house is sold. The interest is carried at cost which approximates fair value, and is included in other assets. 
On August 31, 1991, the Company sold all of the outstanding capi­tal stock of an inactive subsidiary to an executive officer for $238,000. In connection with the sale, the Company loaned the executive officer $238,000 and made an additional $254,057 loan to the inactive subsidiary. Both loans bore interest at the rate of 9%. The $254,057 loan was repaid in February, 1994. The $238,000 is due June 30, 1995 .  
In February, 1994 the Company loaned $308,108 to a company owned by an executive officer. The loan is collateralized by the pledge of the executive officer's common stock in the Company and is due November 30, 2006. The loan bears interest at 5 . 5%.  
On September l ,  1992, the Company loaned $250,000 to an exec­utive officer. The note included interest at floating rates which were expected to approximate 8% on average and was due on August 31, 2001. The loan was collateralized by the executive officer's residence and was repaid in June, 1994. The amount receivable from the executive officer at December 31, 1993, including accrued interest, was $270,000. 
On July 1, 1993, the Company purchased a 60% interest in a com­pany owned by an executive officer for $400,000. The Company's interest was sold back to the executive officer on July 1, 1994. 
























In connection with the merger with Preferred, the Company ter­
minated the employment of a former executive officer of Preferred. 
Accordingly, under an existing employment agreement, the 
Company will pay the former executive officer severance in the 
amount of $304,500, to be increased through 1997, by approxi­
mately 5% per year. 
In 1994, the Company loaned $150,000 to an executive officer. 
The note includes interest at 8% and is due upon the earlier of the 
sale of his residence or his departure from the Company. The loan 
is not collateralized. The amount receivable from the executive 
officer at December 31, 1994 is $150,000. 
The Company also maintains employment agreements with cer­
tain of its executive officers providing for severance payments of up 
to two years' current base salary in the event any of the agreements 
are terminated, under certain specified conditions. 
1 1  Fair Value of Financial Instruments 
Statement of Financial Accounting Standards No. 107, Disclosures 
about Fair Value of Financial Instruments ("SFAS 107"), requires 
isclosure of fair value information about financial instruments, 
whether or not recognized in the balance sheet, for which it is 
practicable to estimate the value. Financial instruments include 
cash and short-term investments, notes receivable, long-term 
investments, other investments and accounts receivable, accounts 
payable and accrued expenses. The methods and assumptions used 
to estimate the fair value of each class of financial instruments are 
as follows: 
Cash and Short-Term Investments 
The carrying amount for cash and short-term investments is a 
reasonable estimate of those assets' fair value. 
Notes Receivable 
Notes receivable consist of loans to officers and other entities (see 
notes 2 and 10). There are no established trading markets for these 
loans which management intends to hold to maturity. Generally, 
fair value is determined by discounting future cash flows using cur­
rent rates at which similar loans would be made to borrowers with 
similar credit ratings and for the same remaining maturities. 
However, due to the nature of certain notes receivable, it is 
impracticable to determine fair value. 
Long-Term Investments 
Fair value for these securities is based on quoted market prices. 
At December 31, 1994, long-term investments are carried at 
fair value. At December 31, 1993, carrying value approximated 
fair value. 
Other Investments 
Due to the nature of certain other investments, it is impracticable 
to determine fair value. With respect to real estate, fair value is 
determined based upon local market data. 
Accounts Receivable, Accounts Payable and Accrued Expenses 
The carrying value of accounts receivable, accounts payable and 
accrued expenses approximates their fair values due to their short 
maturities. 
1 2  Commitments and Contingencies 
The Company is involved in litigation arising in the normal 
course of business. The Company believes that resolution of these 
matters will not result in any payment that, in the aggregate, 
would be material to the financial position or results of operations 
of the Company. 
In 1994, the Company established a $22.4 million letter of credit 
on behalf of one of its customers. The letter had not been drawn 
upon as of December 3 1, 1994. 
1 3  Discontinued Operations 
The Company had administrative and financial advisory agree­
ments with Four Winds, Inc. and its affiliates. On September 30, 
199 1, the Company and Four Winds, Inc. and its affiliates, in 
exchange for $20 million, agreed to terminate agreements under 
which the Company had been providing them with administrative 
services and to settle a $2.9 million receivable. In accordance with 
the agreement, on October 3 1, 199 1 a definitive agreement was 
signed and the Company received cash in the amount of $ 18.7 
million and a note in the principal amount of $1.3 million due 
October 30, 1995. _The note bears interest at 10% annually, 
payable quarterly, and its payment is collateralized by U.S. 
Treasury securities. 
This transaction resulted in the discontinuation of the Company's 
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operating results and the interest income related to the above note 
have been classified as discontinued operations for 1992 in the con­
solidated financial statements. Interest income in 1994 and 1993 is 
included in investment income. 
Details of the income (loss) from discontinued operations for the 
years ended December 31, 1994, 1993 and 1992 are as follows: 
Interest income Income before income ta xes Provision for income ta xes Income (loss) after income ta xes 




1 993 1 992 
$ $4 1 3,000 
4 1 3,000 
5 1 0,677 1 56,940 
$(5 1 0,677) $256,060 
Investments in debt securities as of December 31, 1994 and 1993 
are summarized as follows: 
Available-for-Sale 
December J 1 ,  1 994 Obligations of States and Municipalities Obligations of U .S .  Government and Agencies 
Maturities: Amortized Cost Aggregate Fair Value 
Amortized Unrealized Unrealized Aggregate Cost 
$48,393,000 $ 
6,623,000 
$55 ,0 1 6,000 $ 
Less Than One Year 
$30,748,000 
$30,688,000 
Gain Loss Fair Value 
- ($423,000) $47,970,000 
- (63,000) 6 ,560,000 
($486,000) $54, 530,000 




$55 ,0 1 6,000 
$54,530,000 
Proceeds from the sale of available-for-sale securities were 
$71,883,000 for the year ended December 3 1, 1994. Realized 
losses from these sales were $59,000. 
Held-to-Maturity 
December J 1 ,  1 993 Commercial Paper Obligations of States and Municipalities Obligations of U .S .  Government and Agencies 
Maturities: Amortized Cost Aggregate Fair Value 
Amortized Cost 
$ 3,065,000 
8 1 , 529,000 
34,356,000 
$ 1 1 8 ,950,000 
Less Than One Year 
$55 ,048,000 
$55 ,053,000 
Unrealized Unrealized Aggregate Gain Loss 
$ - $ -
320,000 -
1 1 ,000 
$33 1 ,000 $ -





8 1 ,849,000 
34,367,000 
$ 1 1 9 ,28 1 ,000 
Total 
$ 1 1 8 ,950,000 
$ 1 1 9 ,28 1 ,000 
1 5 Subsequent Events 
In February, 1995, the Company entered into a definitive agree­
ment for the sale of its National Footcare Program, Inc. subsidiary 
back to its original owner and founder, Dr. Claude Oster, for 
book value. 
On February 15, 1995, the Company completed its acquisition 
of Health Management Strategies International, Inc. ("HMS") 
of Alexandria, Virginia for $ 14 million in cash. HMS provides 
managed behavioral health services. 
1 6  Selected Quarterly Financial Data (Unaudited) 
Earnings 
(In thousands, (loss) from 
except continuing 
per share operations Net Earnings 
amounts) Costs of before earnings (loss) 
Quarter Revenues servICes ta xes (loss) per share 
1994 First $2 1 6,350 $ 1 72 ,572 $ 1 8 ,038 $ 1 0,777 $ 0.26 Second 238,27 1 1 89,735 20,43 1 1 2,207 0 .29 
� 
Third 252,3 1 0  1 94,549 1 8 , 1 53 1 1 ,025 0.26 &) Fourth 269,472 206,775 25 ,95 1 1 5 ,6 1 2  0 .38 Year $976,403 $763,63 1 $ 82,573 $ 49,62 1 $ 1 . 1 9  




eport of Independent Accountonts 
To the Stockholders and Boa rd of Directors of 
Value Health, Inc.:  
We have audited the accompanying consolidated balance sheets of Value Health, Inc. and its subsidiaries as of December 3 1 ,  1994 and 1993, and the related consolidated statements of operations, changes in stockholders' equity and cash flows for each of the three years in the period ended December 3 1 ,  1994. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial state­ments based on our audits . We did not audit the financial state­ments of Preferred Health Care Ltd. for the years ended December 3 1 ,  1993 and 1992 or of Rx Net, Inc. for the year ended December 3 1 ,  1992, which statements reflect revenues of approximately 1 6% for the years ended December 3 1 ,  1993 and 1992, and total assets of approximately 1 7% as of December 3 1 ,  1993, of the related consolidated totals .  Those statements were audited by other auditors whose reports have been furnished to us, • and our opinion, insofar as it relates to amounts included for these subsidiaries, which are wholly-owned subsidiaries ofValue Health, Inc. ,  is based solely on the report of such other auditors. 
e conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and per­form the audits to obtain reasonable assurance abour whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. 
In our opinion, based on our audits and the reports of other audi­tors, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Value Health, Inc. and its subsidiaries as of December 3 1 ,  1994 and 1993, and the results of their operations and cash flows for each of the three years in the period ended December 3 1 ,  1994, in conformity with generally accepted accounting principles. 
As stated in note 1 ,  the Company adopted the provisions of Statement of Financial Accounting Standards No. 1 1 5 ,  Accounting for  Certain Investments in  Debt and Equity Securities, as ofJanuaty 1 ,  1994. 
-� '-� Hartford, Connecticut February 22, 1995 
t, y q 
Corporate Information 
Ma rket Price Range of Common Stock 
The following table sets forth the range of high and low sales prices of the Company's Common Stock on the New York Stock Exchange. 




c . Board of Directors 
Robert E. Patricelli David J. McDonnell, D.S.W. Chairman of the Board Former Chairman of the Board and Chief Executive Officer and Chief Executive Officer Value Health, Inc. Preferred Health Care Ltd. 
William J. McBride Walter J. McNerney President and Herman Smith Professor Chief Operating Officer of Health Policy Value Health, Inc. fl. Kellogg Graduate School of Management, Health Services 
Steven J. Shulman Management Program, Executive Vice President Northwestern University Value Health, Inc. 
Principal Officers and Senior Management Committee 
Robert E. Patricelli Chairman of the Board and Chief Executive Officer Value Health, Inc. 
Steven J. Shulman Executive Vice President Value Health, Inc. 
David M. Wurzer Vice President, Treasurer and Chief Financial Officer Value Health, Inc. 
Rodman W. Moorhead III Senior Managing Director E.M. Warburg, Pincus & Co. , Inc. 
Constance B. Newman Under Secretary and Chief Operating Officer Smithsonian Institution 
John L. V ogelstein Vice Chairman of the Board and President, E.M. Warburg, Pincus & Co. , Inc. 
William J. McBride President and Chief Operating Officer Value Health, Inc. 
Paul M. Finigan Vice President, General Counsel and Secretary Value Health, Inc. 








Leslie D. Michelson Chairman and Chief Executive Officer Value Health Sciences, Inc. 
Charlton C. Tooke President and Chief Executive Officer Value Behavioral Health, Inc. 
James E. Buncher Chairman, President and Chief Executive Officer Community Care Network 
Barry M. Smith Chairman, President and Chief Executive Officer ValueRx Pharmacy Program, Inc. 
David G. Noone President and Chief Executive Officer Value Health Insurance Services Group 






Stock Exchange Value Health common stock is traded on the New York Stock Exchange under the symbol "VH. " Options on Value Health common stock are traded on the Chicago Board of Options Exchange under the symbol "VH." At December 31, 1994, there were approximately 40,459,000 shares outstanding and approxi­mately 20,000 shareholders. 
Transfer Agent Mellon Securities Transfer Services of East Hartford, Connecticut, serves as the transfer agent for Value Health common stock. 
Notice of 1 0-K Annual Report The Form 10-K Annual Report ofValue Health, Inc. filed with the Securities and Exchange Commission is available without charge after March 31 of each year to stockholders and prospective investors . Requests should be made to the Investor Relations Department at Value Health's corporate office. 
Annual Meeting The annual meeting of Value Health shareholders will be held on May 4, 1995 at 10 A.M. at the Avon Old Farms Hotel in Avon, Connecticut. 
Investor Inquiries Investor inquiries should be directed to the Investor Relations Department at Value Health's corporate office. 
News releases and quarterly reporrs are available 24 hours a day via fax. Call "Company News On Call ," 1-800-758-5804, Ext. 932938 .  
Value Health, Inc. 22 Waterville Road Avon, CT 06001 Phone: 203-678-3400 Fax: 203-677-1752 
l_ 
Principal Company Addresses 
Value Health, Inc. 22 Waterville Road Avon, CT 06001 Phone: 203-678-3400 Fax: 203-677-1752 
Lewin-VHI,  Inc. 9302 Lee Highway Suite 500 Fairfax, VA 22031 Phone: 703-218-5500 Fax: 703-218-5501 
Value Behavioral Health, Inc. 3110 Fairview Park Drive Falls Church, VA 22042 Phone: 703-205-7000 Fax: 703-205-6505 
Value Health Insurance Services Group 15 River Road Suite 300 Wilton, CT 06897 Phone: 203-761-7300 Fax: 203-761-7405 
Value Health Sciences, Inc. 2400 Broadway Suite 100 Santa Monica, CA 90404 Phone: 310-315-7400 Fax: 310-315-7480 




0 printed on recycled paper 
Front cover design: Michelangelo's David 
is shown half in its original form and half as 
seen through an advanced imaging device, 
thereby combining art and science. We do 
this because medicine is both the art of caring 
for another human being and the science of 
diagnosis and treatment. Value Health seeks 
this combination in its produces and services 
. . .  the best in the art of caring and the best 
in the science of appropriate care. 
��!E!YALUE HEALTH 
Value Health, Inc. 
22 Waterville Road 
Avon, Connecticut 0600 1 
203 678-3400 
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